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About this report
The Trends and Developments report presents a 
top-level overview of the drug phenomenon in Europe, 
covering drug supply, use and public health problems 
as well as drug policy and responses. Together with the 
online Statistical Bulletin, Country Overviews and 
Perspectives on Drugs, it makes up the 2015 European 
Drug Report package.
About the EMCDDA
The European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) is the central source and 
confirmed authority on drug-related issues in Europe. 
For over 20 years, it has been collecting, analysing and 
disseminating scientifically sound information on drugs 
and drug addiction and their consequences, providing 
its audiences with an evidence-based picture of the 
drug phenomenon at European level.
The EMCDDA’s publications are a prime source of 
information for a wide range of audiences including: 
policymakers and their advisors; professionals and 
researchers working in the drugs field; and, more 
broadly, the media and general public. Based in Lisbon, 
the EMCDDA is one of the decentralised agencies of 
the European Union.
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5I Preface
We are proud to present the 20th annual analysis of Europe’s drug situation in the form of 
the European Drug Report (EDR) 2015.
This year’s report contains a comprehensive overview of Europe’s drug problem and the 
measures being taken to tackle it. The Trends and Developments report is at the centre of 
the interlinked set of products comprising the EDR package. Building on European and 
national data, it provides top-level insights into key trends, responses and policies, 
together with in-depth analyses of topical issues. Brand new analyses on psychosocial 
interventions, drug consumption facilities, misuse of benzodiazepines and heroin 
trafficking routes are included in the package. 
The integrated, multimedia information package that forms the EDR today, however, sits in 
contrast to the EMCDDA annual report on the drug situation released in 1996. For the 
EMCDDA, 20 years ago, the challenge of establishing surveillance systems, harmonised 
among 15 EU Member States, must have seemed daunting. It is, therefore, an impressive 
achievement that the fledgling monitoring mechanisms established in 1995 have now 
matured into a European system encompassing 30 countries, which is globally recognised.
While we believe the EMCDDA has made a valuable contribution to the progress that has 
been achieved, we also acknowledge that our work is dependent on close collaboration 
with our partners. Fundamentally, it is the investment made by Member States in 
developing robust national drug information systems that makes the European analysis 
provided here possible.
This report is based on data collected by the Reitox network of national focal points, 
working closely with national experts. The analysis also benefits from ongoing collaboration 
with our European partners: the European Commission, Europol, the European Medicines 
Agency and the European Centre for Disease Prevention and Control. We also wish to 
acknowledge the contribution of numerous European research groups and initiatives, 
without whose work our report would be far less rich.
Not only has our report changed beyond recognition in the last 20 years. So too has the 
extent and nature of the European drug problem. When the agency was established, 
Europe was in the middle of a heroin epidemic, and the need to reduce HIV transmission 
and AIDS-related deaths were main drivers of drug policy. Today, both heroin use and HIV 
problems remain central to our reporting — but they sit in a context that is more optimistic 
in terms of developments and more informed in terms of what constitutes effective public 
health responses. The complexity of the problem, however, is now far greater. This is 
reflected by the fact that many of the substances featured in this report were virtually 
unknown in Europe when the agency was established.
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Today, the European drug markets continue to change and evolve rapidly. This is illustrated 
by the fact that, in 2014, over a hundred new psychoactive substances were detected, and 
risk assessments were conducted on six new drugs — both of these numbers are record 
highs. To keep pace with these changes, and to ensure that the analysis we provide is 
informed by new developments, the EMCDDA continues to work closely with researchers 
and practitioners. As an agency, we have always recognised the importance of delivering 
sound and policy-relevant information in a timely fashion. We remain committed to this 
goal, and to ensuring that whatever the nature of the drug problem we face, Europe’s 
responses will be supported by an information system that remains viable, relevant and fit 
for purpose. 
João Goulão 
Chairman, EMCDDA Management Board
Wolfgang Götz 
Director, EMCDDA


9I Introductory note and acknowledgements
This report is based on information provided to the EMCDDA by the EU Member States, the 
candidate country Turkey, and Norway, in the form of a national report. 
The purpose of the current report is to prove an overview and summary of the European 
drug situation and responses to it. The statistical data reported here relate to 2013 (or the 
most recent year available). Analysis of trends is based only on those countries providing 
sufficient data to describe changes over the period specified. The reader should also be 
aware that monitoring patterns and trends in a hidden and stigmatised behaviour like drug 
use is both practically and methodologically challenging. For this reason, multiple sources 
of data are used for the purposes of analysis in this report. Although considerable 
improvements can be noted, both nationally and in respect to what is possible to achieve 
in a European-level analysis, the methodological difficulties in this area must be 
acknowledged. Caution is therefore required in interpretation, in particular when countries 
are compared on any single measure. Caveats and qualifications relating to the data are to 
be found in the online version of this report and in the Statistical Bulletin, where detailed 
information on methodology, qualifications on analysis and comments on the limitations in 
the information set available can be found. Information is also available there on the 
methods and data used for European-level estimates, where interpolation may be used.
The EMCDDA would like to thank the following for their help in producing this report:
 the heads of the Reitox national focal points and their staff;
  the services and experts within each Member State that collected the raw data for this 
report;
 the members of the Management Board and the Scientific Committee of the EMCDDA;
  the European Parliament, the Council of the European Union — in particular its 
Horizontal Working Party on Drugs — and the European Commission;
  the European Centre for Disease Prevention and Control (ECDC), the European 
Medicines Agency (EMA) and Europol;
  the Pompidou Group of the Council of Europe, the United Nations Office on Drugs and 
Crime, the WHO Regional Office for Europe, Interpol, the World Customs Organisation, 
the European School Survey Project on Alcohol and Other Drugs (ESPAD), the Sewage 
Analysis Core Group Europe (SCORE) and the Swedish Council for Information on 
Alcohol and Other Drugs (CAN);
  the Translation Centre for the Bodies of the European Union, Missing Element Designers, 
Nigel Hawtin and Composiciones Rali.
Reitox national focal points
Reitox is the European information network on drugs and drug addiction. The 
network is comprised of national focal points in the EU Member States, the 
candidate country Turkey, Norway and at the European Commission. Under the 
responsibility of their governments, the focal points are the national authorities 
providing drug information to the EMCDDA. The contact details of the national focal 
points may be found on the EMCDDA website.
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Drug market dynamics in 
Europe: global influences and 
local differences
The main findings of the EMCDDA’s 
latest analysis of the drug problem in 
Europe point to a situation where long-
term patterns and trends continue, but 
new developments in patterns of use 
and responses are emerging. The 
importance of global factors on drug 
supply and policy discussions are 
evident in this year’s analysis, while 
local patterns of use and responses to 
problems are both at the forefront of 
new trends. The boundary between the 
market categories of ‘old’ and new 
drugs is becoming harder to define, and 
just as new drugs increasingly mimic 
established substance types, so 
responses to new drugs may mirror 
evidence-based responses to problems 
with established drugs.
I Cannabis in the spotlight
While initiatives being undertaken in the Americas on the 
regulated sale of cannabis and cannabis products are 
generating international interest and debate, in Europe, 
discussion on cannabis remains largely focused on the 
potential health costs associated with this drug. New data 
highlight the major role played by cannabis in drug-related 
crime statistics, with the drug accounting for 80 % of 
seizures and cannabis use or possession for personal use 
accounting for over 60 % of all reported drug law offences 
in Europe (see figure). In addition, the production and 
trafficking of this drug is recognised as an area of growing 
importance for law enforcement efforts due to the 
increased involvement of organised crime. Considerable 
diversity exists, however, between countries in sentencing 
practices for cannabis-related supply offences, with 
national experts indicating that penalties for a first-time 
offence of supplying one kilogram of cannabis may range 
from less than 1 year to 10 years in prison. 
New data also show the growing importance of cannabis 
within drug treatment systems in Europe, with an increase 
in the number of treatment demands for cannabis-related 
problems. This increase needs to be understood in the 
context of service provision and referral practice. For 
example, in some countries, directive referrals from the 
criminal justice system account for a high proportion of 
treatment entrants. The data are also influenced by 
differing national definitions and practices in respect to 
what constitutes treatment for cannabis-related disorders, 
which can range from a brief intervention session delivered 
online to admission to residential care. The availability of 
12
European Drug Report 2015: Trends and Developments
MDMA. After a period in which tablets sold as ‘ecstasy’ had 
a reputation among consumers for poor quality and 
product adulteration, which was supported by forensic 
evidence, high-purity MDMA powder and tablets are now 
more commonly available. The introduction of high-purity 
powder or crystal MDMA appears to be a deliberate 
strategy for differentiating this form of MDMA and making 
it more attractive to consumers. Similarly, high-dose 
tablets with distinctive shapes and logos are appearing, 
presumably with the same marketing objective. Over the 
last year, the EMCDDA and Europol have issued an alert 
warning of health risks linked to the consumption of very 
high purity MDMA products. In addition, alerts have also 
been issued about tablets sold as ecstasy, but containing 
PMMA, sometimes in combination with MDMA. The 
pharmacology of this drug makes it particularly worrying 
from a public health point of view.
For MDMA, and synthetic substances in general, product 
quality and supply is largely driven by the availability of 
precursor chemicals. Innovation in this area is also 
apparent, particularly in relation to production practices. 
This can be seen in respect to routes of chemical synthesis 
and in the high capacity of some of the production sites 
recently detected. It has also been suggested that, in some 
countries, the availability of new psychoactive substances 
may play a role. For example, the availability of high-quality 
synthetic cannabinoids and cathinones has sometimes 
been reported as offering direct competition to low-quality, 
and relatively more expensive, established drugs. 
treatment for cannabis users appears also to be changing, 
probably in response to both a greater awareness of the 
need for services and, in some countries, treatment 
capacity becoming available due to a decline in demand 
for services for other types of drug use. Irrespective of 
treatment type, for cannabis-related problems, the 
evidence supports psychosocial interventions — these 
approaches are explored in an analysis accompanying this 
report. In addition, evidence is emerging from studies in 
accident and emergency settings of increasing cases of 
acute health problems associated with high-potency 
cannabis products. Against a background of the greater 
availability of high-potency cannabis products, 
improvements are clearly now required in the monitoring 
of acute problems associated with the use of this drug.
I  Is market competition leading to higher strength products? 
This year’s round of data collection found evidence of 
purity or potency increases in the medium or short term for 
all the most commonly used drugs in Europe. The reasons 
for this are likely to be complex, but appear to include both 
technical innovation and market competition. In the case 
of cannabis, where domestically produced, high-potency 
herbal products have taken an increasing market share in 
recent years, the data now point to an increase in the 
potency of imported resin, which is likely to be associated 
with changes in production practices. Innovation in the 
market and increased purity are also evident in the case of 
MOST DRUG LAW OFFENCES RELATE TO CANNABIS
Cannabis use* 
Cannabis supply
Other drugs use*
Other drugs supply
781 000
116 000
223 000
86 000
42 000 Other oences
1.25 million
Other drugs Cannabis 
Other
oences
2 % 
Use*
63 %
Supply
9 %
drug law oences
* ‘Use’ includes oences for use and possession for personal use.
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including tobacco and alcohol. Less well documented, but 
explored in a new analysis accompanying this report, is 
misuse of benzodiazepines among high-risk drug users. 
The misuse of benzodiazepines in combination with 
opioids is associated with elevated risk of drug overdose. 
Formulating effective responses to reduce overdose 
deaths remains a key policy challenge in Europe. 
Developments in this area include the introduction of 
targeted strategies, the provision of naloxone programmes 
and prevention initiatives targeting high-risk groups. Some 
countries have a long-established practice of providing 
‘supervised drug consumption rooms’, with the intention of 
engaging with hard-to-reach drug users and reducing 
drug-related harms, including overdose deaths. A review of 
services delivered in these settings accompanies this 
report.
Historically, a main driver for drug policy and responses in 
respect to heroin, particularly injecting use, was the need 
to reduce HIV risk behaviour and transmission. Recent 
outbreaks and the situation in a few European countries 
underline the need for continued vigilance and ensuring 
that service provision levels are adequate. Nonetheless, 
the long-term picture shows clear improvement overall and 
illustrates the impact that provision of appropriate services 
can have. This message is relevant to efforts to address the 
relatively high rates of hepatitis C infection still found 
among injecting drug users. Here, new and effective 
treatments are becoming available, although treatment 
costs are high. The EMCDDA notes, however, that in some 
countries, and with support at European level, efforts are 
being made to improve the situation. 
I Changes in the European heroin market
Problems related to heroin still account for a large share of 
the drug-related health and social costs in Europe, 
although recent trends in this area have been relatively 
positive. Recent data continue to show declining treatment 
demand and heroin-related harms, but a number of market 
indicators raise concern. UN estimates suggest a 
substantial increase in opium production in Afghanistan, 
the country supplying most of the heroin consumed in 
Europe. A potential knock-on effect in availability is 
therefore possible, and it is worrying that estimates of the 
purity of heroin available in Europe are on the rise. In some 
countries where purity increases have been observed, 
overdose deaths have also increased in recent data. It is 
unclear if these increases are linked, but this question 
warrants research attention. The clandestine nature of the 
drug market means that any analysis of its dynamics must 
be made with caution. Nonetheless, evidence is emerging 
of innovation in the supply of heroin to markets in Europe, 
and potential for a resurgence of the drug exists. Signs of 
change in heroin supply include the detection of heroin 
processing laboratories in Europe — not seen before — as 
well as evidence of adaptation in heroin trafficking routes 
and in the modus operandi of criminal groups. The transit 
of heroin from Pakistan and Afghanistan into Europe 
through Africa continues to cause concern. Seizure data 
also point strongly to the role that Turkey plays as a 
geographical gateway for drugs being shipped into and out 
of the European Union, and heroin seizures in that country 
have partially recovered from a low point recorded in 2011. 
These issues are explored in an analysis on heroin 
trafficking accompanying this report.
I Older clients bringing new challenges to services
Any potential increases in heroin availability must be 
viewed in the context of the overall stagnation in demand 
for this drug, driven in a large part by both a decline in 
recruitment into heroin use and the enrolment of many of 
those with heroin problems into treatment services. In 
addition to the therapeutic benefits of treatment provision, 
Europe’s overall high rate of treatment coverage, estimated 
at 50 % of cases or more, is likely to make the European 
Union a smaller and potentially less attractive market for 
those supplying this drug. Heroin dependence is a chronic 
condition, and earlier predictions that services would need 
to adapt to the needs of an ageing cohort are borne out in 
the analysis presented in this report. Provision of an 
appropriate health and social service response for this 
group is therefore a growing challenge for drug services. 
Responses are complicated by problems experienced by 
this cohort related to long-term use of other substances, 
14
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I  Combination of sexual and drug risk-taking behaviour: a growing area of concern
Situational analyses provided here often focus on 
comparing differences between countries. It is important 
to remember, however, that some drug-taking behaviour is 
linked to socio-cultural factors that are not necessarily 
country-specific. An example of this can be seen in some 
large European cities, where concerns exist about the 
spread of stimulant injection among small groups of men 
who have sex with men. Practices involving the so-called 
slamming of methamphetamine, cathinones and other 
substances in the context of ‘chem-sex’ parties have 
implications for both HIV transmission and sexual health 
services and highlight a need for joined-up responses in 
this area. This phenomenon runs contrary to the overall 
European trend in injecting drug use, which is declining in 
most populations, and underlines a general need to 
increase the attention given to the link between drugs and 
sexual risk-taking behaviour.
I  The Internet and apps: emerging virtual drug markets
Reflecting developments elsewhere, there is a growing 
trend for both drug and sexual health services to utilise the 
Internet and apps as platforms for delivering services. 
Information provision on drugs, prevention programmes 
and outreach services are, in varying degrees, relocating 
from physical spaces to virtual environments. Following 
suit, many drug treatment programmes are now 
established online, increasing their accessibility to both 
new and existing target groups. 
Awareness is also growing of the potential role of the 
Internet in drug supply and marketing. Both new 
psychoactive substances and established drugs are being 
offered for sale on the surface and deep web, although the 
extent to which this occurs is unknown. Bearing in mind 
that in most other fields of commerce, consumer activity is 
moving from physical to online marketplaces, online drug 
markets may become an important area for focusing our 
monitoring activity in the future. This is also likely to be a 
challenging area for drug control policies, as developments 
can occur rapidly, such as the introduction of new 
marketplaces and cryptocurrencies. Existing regulatory 
models will need to be adapted to perform in a global and 
virtual context. 
I  Prevalence of new psychoactive substances: the need to improve our understanding 
The Internet has also been an important driver for the 
development of the market for new psychoactive 
substances, both directly, through online stores, and 
indirectly, by allowing producers easy access to research 
and pharmaceutical data, and by providing potential 
consumers with a forum for information exchange. Public 
and policy concern about the use of new psychoactive 
substances has grown considerably in a short time. 
However, our understanding of both the extent of use and 
the associated harms has not kept pace with 
developments. This is beginning to change, with more 
countries attempting to estimate the prevalence of use of 
these substances. Estimation in this area is challenging for 
methodological reasons; to date, national estimates have 
been difficult to compare. Some comparable data are 
available, however. While acknowledging that the recent 
Flash Eurobarometer on young people and drugs has 
methodological limitations as a prevalence estimation tool, 
it does provide data from all EU Member States, using a 
standardised questionnaire. The study results would 
suggest that lifetime use of new psychoactive substances 
remains at low levels among young people in most 
countries. 
Other studies now becoming available provide windows on 
particular forms of new psychoactive substance use. 
Although these studies cannot be considered 
representative, they show that the use of new psychoactive 
substances occurs among groups as diverse as school 
students, party-goers, psychonauts, prisoners and injecting 
drug users. There is a growing understanding of 
motivations for use. Again, these are diverse, and include 
factors such as legal status, availability and cost, as well as 
the desire to avoid detection and user preferences for 
particular pharmacological properties. There is also 
evidence to suggest that new psychoactive substances 
have functioned as market substitutes at times of low 
availability and poor quality of established illicit drugs. For 
example, the popularity of mephedrone in some countries 
at the start of this decade has been attributed in part to 
the poor quality of illicit stimulants such as MDMA and 
cocaine. It will be interesting to see whether the increases 
now being observed in the potency and purity of 
established drugs will have implications for the 
consumption of new psychoactive substances.
15
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AT A GLANCE — ESTIMATES OF DRUG USE IN THE EUROPEAN UNION
NB: For the complete set of data and information on the methodology see the accompanying online Statistical Bulletin.
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I  Number of new psychoactive substances identified on the drug market continues to increase
While the use of new psychoactive substances appears to 
be limited overall, the pace of emergence of new drugs has 
not diminished. Reports to the EU Early Warning System 
indicate that both the variety and the quantity of new 
psychoactive substances on Europe’s market are still 
increasing. In 2014, 101 new psychoactive substances 
were detected for the first time, and it is interesting to note 
how the new drugs coming onto the market, mainly 
synthetic cannabinoids, stimulants, hallucinogens and 
opioids, mirror the established substances. Also in this 
report, the EMCDDA presents new data on the seizure of 
these substances. An important clarification here is that 
the method of data collection differs from that used for the 
regular monitoring of drug seizures, and the two datasets 
cannot be directly compared. 
An unprecedented six risk assessments were conducted in 
2014; a reminder of the importance of keeping a focus on 
the substances that cause particular harm. This 
achievement was helped by the improved availability of 
information on both hospital emergencies and toxicology. 
Despite improvements in the monitoring of acute drug-
related harms, the limited capacity in this area continues 
to restrict our view of the public health consequences 
related not just to new psychoactive substances but, more 
generally, to contemporary drug consumption patterns. 
Health and social responses to the challenges posed by 
new drugs have been piecemeal and slow to emerge, but 
are now gathering momentum. These include a wide range 
of efforts mirroring the full spectrum of responses to 
established illicit substances, from drug education and 
training activities, to user-led consumer protection 
interventions on the Internet and needle and syringe 
exchange programmes based in low-threshold services.

 Europe is an important market  
 for drugs, supported by both  
 domestic production and drugs  
 trafficked from other regions 
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Drug supply and the market
In the global context, Europe is an 
important market for drugs, supported 
by both domestic production and drugs 
trafficked from other regions. Latin 
America, West Asia and North Africa are 
important source areas for drugs 
entering Europe, and some drugs and 
precursors are transited through Europe 
en route to other continents. Europe is 
also a producing region for cannabis 
and synthetic drugs, with cannabis 
mostly being produced for local 
consumption, while some of the 
synthetic drugs are being manufactured 
for export to other parts of the world.
Monitoring drug markets, supply and laws
The analysis presented in this chapter draws on 
reported data on drug seizures, dismantled drug 
production facilities, drug law offences, retail drug 
prices, purity and potency. In some areas, the 
absence of seizure data from some countries makes 
the analysis of trends difficult. Full data sets and 
methodological notes can be found in the online 
Statistical Bulletin. It should be noted that trends can 
be influenced by a range of factors which include law 
enforcement activity levels and the effectiveness of 
interdiction measures.
Also presented here are data on seizures of new 
psychoactive substances reported to the EU Early 
Warning System by the national partners of the 
EMCDDA and Europol. As this information is drawn 
from case reports rather than routine monitoring 
systems, these seizure estimates represent a 
minimum. Data will be influenced by factors such as 
increasing awareness of these substances, their 
changing legal status and the reporting practices of 
law enforcement agencies. A full description of the 
Early Warning System can be found on the EMCDDA 
website under Action on new drugs.
Comprehensive data on European drug laws is 
available in the online European Legal Database on 
Drugs. The implementation of these laws is 
monitored through reports on drug law offences. 
Sizeable markets for cannabis, heroin and amphetamines 
have existed in many European countries since the 1970s 
and 1980s. Over time, other substances also established 
Chapter 1
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I  Drug seizures in Europe: dominated by cannabis
Around one million seizures of illicit drugs are reported 
annually in Europe. Most of these are small quantities of 
drugs confiscated from users, although multi-kilogram 
consignments seized from traffickers and producers 
account for a large proportion of the overall quantity of 
drugs seized. 
Cannabis is the most commonly seized drug, accounting 
for about eight out of ten seizures in Europe (Figure 1.1), 
and reflecting its relatively high prevalence of use. Cocaine 
ranks second overall, with more than double the number of 
seizures reported for either amphetamines or heroin. The 
number of ecstasy seizures is relatively low. 
In 2013, about two-thirds of all seizures in the European 
Union were reported by just two countries, Spain and the 
United Kingdom, although considerable numbers of 
seizures were also reported by Belgium, Germany, Italy and 
four Nordic countries. It should also be noted that recent 
data on the number of seizures are not available for France 
and the Netherlands — countries that reported large 
numbers of seizures in the past — and Poland. The 
absence of these data adds uncertainty to the analysis 
reported here. In addition, Turkey is an important country 
themselves — including MDMA in the 1990s and cocaine 
in the 2000s. The market continues to evolve, with the last 
decade witnessing the emergence of a wide range of new 
psychoactive substances. The nature of the illicit drug 
market has also been changing as a result of globalisation, 
technology and the Internet. Additional challenges are 
presented by innovation in drug production and trafficking 
methods and the establishment of new trafficking routes. 
Measures aimed at preventing the supply of drugs involve 
many players in government and law enforcement and 
often depend on international cooperation. The stance that 
countries take is also reflected in their national drug laws. 
Data on arrests and seizures are the most well-
documented indicators of drug-supply disruption efforts.
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for drug seizures, with some of the drugs intercepted there 
being intended for consumption in other countries, both in 
Europe and in the Middle East. 
Data are also presented here on the growing number of 
seizures of new psychoactive substances reported to the 
EU Early Warning System. In 2013, about 35 000 seizures 
were reported, primarily synthetic cannabinoids and 
cathinones (Figure 1.2). This should be regarded as a 
minimum estimate due to the lack of routine reporting in 
this area. It should be noted that these data are not directly 
comparable with the data on established drugs such as 
cannabis.
I Cannabis products: a diverse market
Two main cannabis products are found on the European 
drugs market: herbal cannabis (marijuana) and cannabis 
resin (hashish). Herbal cannabis consumed in Europe is 
both cultivated domestically and trafficked from external 
countries. Most cannabis resin is imported by sea or by air 
from Morocco. 
The number of seizures of herbal cannabis overtook that of 
cannabis resin in Europe in 2009, and the gap has 
continued to widen (Figure 1.3). This is probably driven, to 
a large extent, by the growing availability of domestically 
produced herbal cannabis in many European countries 
and is mirrored in increasing seizures of cannabis plants. 
Nevertheless, the quantity of cannabis resin seized in the 
European Union is still much higher than that of herbal 
cannabis (460 tonnes versus 130 tonnes). This is, in part, 
explained by the fact that cannabis resin is trafficked in 
volume over large distances and across national borders, 
making it more vulnerable to interdiction.
The recent emergence of synthetic cannabinoid products 
has added a new dimension to the cannabis market. Over 
130 different synthetic cannabinoids have been detected 
in recent years. Most of these substances appear to be 
manufactured in China. After being shipped in powder 
form to Europe, the chemicals are typically added to plant 
material and packaged for sale as ‘legal high’ products.
In 2013, 671 000 seizures of cannabis were reported in 
the European Union (431 000 of herbal cannabis, 240 000 
of cannabis resin). There were a further 30 000 seizures of 
FIGURE 1.2
Number of seizures of new psychoactive substances reported to the EU Early Warning System:  
breakdown by main substance category of seizures in 2013 (left) and trends (right)
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cannabis plants. In addition, over 10 000 seizures of 
synthetic cannabinoids were reported by EU countries to 
the Early Warning System in 2013, rising sharply from 
2011 levels and a further 11 000 seizures were reported 
by Turkey (see Figure 1.4).
In the analysis of the quantity of cannabis seized, a small 
number of countries are disproportionately important due 
to their location on major cannabis trafficking routes. 
Spain, for example, as a major point of entry for cannabis 
produced in Morocco, reported more than two-thirds of the 
total quantity of cannabis resin seized in Europe in 2013 
(Figure 1.5). In respect to herbal cannabis, recent large 
increases have been reported in Greece, Spain and Italy. In 
recent years, Turkey has been seizing larger quantities of 
herbal cannabis than any other European country, and the 
amount reported in 2013 (180 tonnes) was more than all 
the EU Member States combined.
Seizures of cannabis plants may be regarded as an 
indicator of the production of the drug within a country. 
Methodological problems mean that data on cannabis 
plant seizures must be considered with caution, 
nevertheless the number of plants seized increased from 
1.5 million in 2002 to 3.7 million in 2013. 
FIGURE 1.3
Trends in number of cannabis seizures and quantity seized: resin (left) and herb (right)
FIGURE 1.4
Seizures of synthetic cannabinoids reported to the EU Early 
Warning System: number of seizures and quantity seized
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Analysis of indexed trends among those countries 
reporting consistently show a large increase in the potency 
(level of tetrahydrocannabinol, THC) of both herbal 
cannabis and cannabis resin between 2006 and 2013. 
Drivers of this increasing potency may include the 
introduction of intensive production techniques within 
Europe and, more recently, the introduction of high 
potency plants in Morocco. 
Indexed trends for cannabis-related drug law offences in 
the European Union also show marked increases between 
2006 and 2013. 
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reports of illicit opioid drugs originating in Europe have 
been limited to the production of homemade poppy 
products in parts of eastern Europe.
Heroin enters Europe along four trafficking routes. The two 
most important are the ‘Balkan route’ and the ‘southern 
route’. The first of these runs through Turkey, into Balkan 
countries (Bulgaria, Romania or Albania) and on to central, 
southern and western Europe. Heroin shipments from Iran 
and Pakistan may also enter Europe by air or sea, either 
directly or transiting through west, southern and east 
African countries. The southern route seems to have 
gained importance in recent years. 
Europe has seen a considerable decline in heroin seizures 
from 2010 onwards, following almost a decade of relative 
stability. Both the number of heroin seizures (32 000) and 
the quantity seized in 2013 (5.6 tonnes) are among the 
lowest levels reported in the last decade. Declining 
seizures in the European Union have coincided with the 
increasing importance of seizures in Turkey (13.5 tonnes in 
2013) where, in each year since 2006, more heroin has 
been seized than in all EU countries combined (Figure 1.6). 
Alongside recent declines in the number of heroin 
seizures, decreases were also observed in indexed trends 
for price and supply offences (see heroin infographic). 
I Opioids: a changing market?
Heroin is the most common opioid on the European drug 
market. Imported heroin has historically been available in 
Europe in two forms: the more common of these is brown 
heroin (its chemical base form), originating mainly from 
Afghanistan. Far less common is white heroin (a salt form), 
which historically came from South-East Asia, but now 
may also be produced in Afghanistan or in neighbouring 
countries. Other opioids seized by law enforcement 
agencies in European countries in 2013 included opium 
and the medicinal products morphine, methadone, 
buprenorphine, fentanyl and tramadol. Some medicinal 
opioids may have been diverted from pharmaceutical 
supplies, while others are manufactured specifically for the 
illicit market. Worryingly, 14 new synthetic opioids have 
been reported to the EU Early Warning System since 2005, 
among which are several highly potent uncontrolled 
fentanyls. 
Afghanistan remains the world’s largest illicit producer of 
opium, and most heroin found in Europe is thought to be 
manufactured there or in neighbouring Iran or Pakistan. 
There are signs that the final stages of heroin 
manufacturing may now be carried out in Europe, as 
indicated by the discovery of two laboratories converting 
morphine into heroin in Spain in 2013–14. Historically, 
FIGURE 1.5
Seizures of cannabis resin and herbal cannabis, 2013
>100
11–100
1–10
<1
No data
>100
11–100
1–10
<1
No data
66
7
11
12
17
5
5
172
149
24
29
8
6
69
7 613 180
Spain
0 50 100 150 200 250 300 350
Other countries
Quantity of cannabis resin seized (tonnes)
Turkey
0 50 100 150 200
Other countries
Quantity of herbal cannabis seized (tonnes)
Number of cannabis resin  
seizures (thousands)
Number of herbal cannabis  
seizures (thousands)
NB: Number of seizures for the 10 countries with highest values. 
25
Chapter 1 I Drug supply and the market
Markets in a number of countries experienced heroin 
shortages in 2010/11, from which few appear to have fully 
recovered. Nonetheless, among those countries reporting 
consistently, indexed trends suggest that heroin purity 
increased in Europe in 2013; and some countries have 
expressed concern about possible increased availability. In 
Turkey, the number of seizures rose in 2013 and the 
quantity seized continued to increase from 2012 levels. 
In addition the United Nations reports a substantial 
increase in opium production in Afghanistan. Taken 
together, there are signals suggesting there is potential for 
the availability of this drug to increase.
FIGURE 1.6
Number of heroin seizures and quantity seized: trends (left) and in 2013 (right)
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I  Cocaine: stable seizures and increased purity 
In Europe, cocaine is available in two forms, the most 
common of which is cocaine powder (a hydrochloride salt, 
HCl). Less commonly available is crack cocaine, a 
smokeable (free base) form of the drug. Cocaine is 
produced from the leaves of the coca bush. The drug is 
produced almost exclusively in Bolivia, Colombia and Peru, 
and is transported to Europe by both air and sea routes. 
The available data indicate that trafficking of cocaine into 
Europe mainly takes place through western and southern 
countries, with Spain, Belgium, the Netherlands, France 
and Italy together accounting for 86 % of the 62.6 tonnes 
seized in 2013 (Figure 1.7). 
In 2013, about 78 000 seizures of cocaine were reported in 
the European Union, amounting to 63 tonnes of the drug. 
The situation has been relatively stable since 2010, 
although both the number of seizures and the volume 
seized are at levels considerably lower than the peak 
values reached in 2006 and 2008 (Figure 1.7). While Spain 
continues to be the country seizing the most cocaine in 
Europe, there are signs of the ongoing diversification of 
trafficking routes into Europe, with seizures of the drug 
recently reported in ports on the eastern Mediterranean, 
Baltic and Black Seas. Overall, indexed trends suggest that 
the purity of cocaine has increased in recent years, while 
the price has remained relatively stable. Indexed trends for 
cocaine-related offences show an increase since 2006.
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I  Amphetamines: increased amphetamine and methamphetamine seizures 
Amphetamine and methamphetamine are closely related 
synthetic stimulants, generically known as amphetamines, 
and these are difficult to differentiate in some datasets. Of 
the two, amphetamine has always been the more common 
in Europe, but recent years have seen increasing reports of 
the availability of methamphetamine on the market. 
Both drugs are manufactured in Europe for domestic use, 
although some amphetamine and methamphetamine is 
also manufactured for export, principally to the Middle 
East and the Far East, respectively. Europe is also a transit 
hub for methamphetamine being trafficked from Africa and 
Iran to the Far East. Data available indicate that 
amphetamine production mainly takes place in Belgium, 
the Netherlands, Poland and the Baltic States and, to a 
lesser extent, in Germany, while methamphetamine 
production is concentrated in the Baltic States and 
central Europe. 
The production of methamphetamine in Europe appears to 
be changing, partly driven by the availability of precursors. 
Methamphetamine production using BMK (benzyl methyl 
ketone) as a principal precursor is centred on Lithuania; 
the drug is exported mainly to northern European 
countries, where it has impacted on the amphetamine 
market. This can be seen in the relatively high seizures 
reported in Norway. Production based on ephedrine and 
pseudoephedrine is centred on the Czech Republic, 
although some is also occurring in Slovakia and now 
Germany. Historically, in the Czech Republic, 
methamphetamine has mainly been produced in small-
scale facilities by users for their own or local use. This is 
reflected in the high number of production sites detected 
in this country (261 dismantled in 2013, out of a total of 
294 in Europe). Recently, however, signs of larger-scale 
production have emerged, with reports of Vietnamese 
organised crime groups producing large volumes of this 
drug for both domestic and external markets. 
FIGURE 1.7
Number of cocaine seizures and quantity seized: trends (left) and 2013 or most recent year (right)
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In 2013, 34 000 seizures of amphetamine were reported 
by EU Member States, amounting to 6.7 tonnes. More than 
half of the total quantity of amphetamine seized was 
accounted for by Germany, the Netherlands and the United 
Kingdom. After a period of relative stability, there was an 
increase in the quantity of amphetamine seized in 2013 
(Figure 1.8). Methamphetamine seizures are far lower, 
accounting for around a sixth of all amphetamines 
seizures in 2013, with 7 000 seizures reported in the 
European Union, amounting to 0.5 tonnes (Figure 1.9). 
There have been increasing trends for both number and 
quantity of methamphetamine seized since 2002. 
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Typically, the average reported purity is higher for 
methamphetamine than for amphetamine samples. And 
although indexed trends, among those countries reporting 
consistently, suggest that amphetamine purity has 
increased in the latest data, the average purity of this drug 
continues to be relatively low.
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FIGURE 1.9
Number of amphetamine seizures and quantity seized: trends (left) and 2013 or most recent year (right)
Number of methamphetamine seizures and quantity seized: trends (left) and 2013 or most recent year (right)
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Netherlands reported seizing 2.4 million MDMA tablets in 
2012, and if a similar figure may be assumed for 2013, it 
can be estimated that 4.8 million MDMA tablets were 
seized in the European Union in that year. This would be 
roughly double the amount seized in 2009. Of note, the 
quantity of MDMA now seized in Turkey (4.4 million MDMA 
tablets) is equal to the total seized in all EU Member States 
(Figure 1.10). This raises questions as to whether these 
drugs were intended for domestic use or for export to the 
European Union or elsewhere.
A recent upturn is also evident in indexed trends of 
MDMA-related offences. Among those countries reporting 
consistently, indexed trends also point to increases in 
MDMA-content since 2010, and the availability of high 
MDMA-content products has prompted joint alerts from 
Europol and the EMCDDA in 2014. Taken together, these 
indicators of the MDMA market all point to recovery from a 
low reached about 5 years ago. 
I  MDMA/ecstasy: increase in high-purity products
The synthetic substance MDMA (3,4-methylenedioxy-
methamphetamine) is chemically related to 
amphetamines, but differs to some extent in its effects. 
Ecstasy tablets have historically been the main MDMA 
product on the market, although they may often contain a 
range of MDMA-like substances and unrelated chemicals. 
After a period when reports suggested that the majority of 
tablets sold as ecstasy in Europe contained low doses of 
MDMA or none at all, recent evidence indicates that this 
may be changing. New data suggest an increased 
availability both of high-content MDMA tablets and of 
MDMA in powder and crystal form. 
Production of MDMA in Europe appears to be concentrated 
around the Netherlands and Belgium, the countries that 
have historically reported the largest numbers of 
production sites for the drug. After evidence of a decline in 
MDMA production at the end of the last decade, there have 
been signs of a resurgence, illustrated by reports of 
large-scale production facilities recently dismantled in 
Belgium and the Netherlands.
Assessing recent trends in MDMA seizures is difficult due 
to the absence of data from some countries that are likely 
to make important contributions to this total. For 2013, no 
data are available from the Netherlands and the number of 
seizures is not available from France and Poland. The 
ECSTASY
34
77 98
144
3 €
5 € 10 €
24 €
Ecstasy supply
oences reported
EU + 2 refers to EU Member States, Turkey and Norway. Price and purity of ecstasy: national mean values – minimum, maximum and interquartile range.
Countries covered vary by indicator.
seizures
13 400
seizures (EU + 2)
million tablets seized
(EU + 2)
9.3
million tablets seized
4.8
18 000
11 000
Ecstasy use/possession
oences reported
3 700
2006
100
2013
59
53
2006
100
2013
80
176
of reported
supply oences
2 %
of reported use/
possession oences
1 %
Indexed trends: 
use/possession and supply oences
Price (EUR/tablet)
Purity (MDMA mg/tablet)
Indexed trends: 
price and purity
Drug law oences Seizures 
31
Chapter 1 I Drug supply and the market
I New stimulants on the illicit market
First introduced as new psychoactive substances, not 
controlled under drug laws, synthetic cathinones such as 
mephedrone, pentedrone and MDPV 
(3,4-methylenedioxypyrovalerone) have become a fixture 
on the illicit drug market in some European countries. 
Cathinones are used in similar ways to, and often 
interchangeably with, other stimulants such as 
amphetamine and MDMA. Most often they are available as 
powders or tablets. Production of cathinones appears to 
take place primarily in China and India. The drugs are then 
imported into Europe, where they are packaged and 
marketed as ‘legal highs’ or sold in the illicit market. The 
Early Warning System has identified more than 70 new 
cathinones in Europe. In 2013, over 10 000 seizures of 
synthetic cathinones were reported to the Early Warning 
System (Figure 1.11).
 Cathinones are used  
 in similar ways to,  
 and often interchangeably  
 with, other stimulants such  
 as amphetamine and MDMA 
FIGURE 1.10
Numbers of MDMA seizures and tablets seized: trends (left) and 2013 or most recent year (right)
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substances most commonly seized, reflecting the relatively 
high demand of cannabis and stimulants on the illicit drug 
market.
In addition to the increasing number of seizures of new 
drugs reported each year in Europe, the number of new 
substances detected continues to grow. In 2014, Member 
States notified the EU Early Warning System of 101 new 
psychoactive substances not previously reported. This 
represented an increase of 25 % compared with 2013 
(Figure 1.12). Thirty-one of these substances are synthetic 
cathinones, making this the largest category of new drugs 
identified in Europe in 2014, followed by 30 synthetic 
cannabinoids. However, another 13 compounds do not fit 
easily into any of the substance groups that are monitored. 
Four of the new psychoactive substances notified in 2014 
are used as active substances in medicines. The EU Early 
Warning System is currently monitoring more than 450 
new psychoactive substances.
I  New psychoactive substances: a marketplace of increasing diversity
The availability of new psychoactive substances on 
Europe’s drug market has rapidly increased over the last 
decade, as evidenced by growing numbers of seizures 
reported to both the Early Warning System and through 
standard monitoring mechanisms. These new drugs 
include substances, synthetic and naturally occurring, that 
are not controlled under international law, and are often 
produced with the intention of mimicking the effects of 
controlled substances. Typically, chemicals are imported 
from suppliers outside Europe, and then prepared, 
packaged and marketed in Europe. Increasingly, however, 
new drugs are produced in Europe in clandestine 
laboratories and sold directly on the market. 
To avoid controls, products are often mislabelled, for 
example as ‘research chemicals’, with disclaimers that 
state the product is not intended for human consumption. 
These substances are marketed through online retailers 
and specialised shops, and increasingly they are offered 
through the same channels used for the supply of illicit 
substances. This market, as well as its relationship to the 
illicit market, is a dynamic one, characterised by the 
continual introduction of new products and control 
measures. Synthetic cannabinoids and synthetic 
cathinones are the groups of new psychoactive 
FIGURE 1.11
Seizures of synthetic cathinones reported to the EU Early Warning 
System: number of seizures and quantity seized
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In September 2014, European-level risk assessments were conducted on 4,4′-DMAR and MT-45. These add to the four risk assessments 
conducted in April 2014 on 25I-NBOMe (a substituted phenethylamine with hallucinogenic effects, sold as a ‘legal’ alternative to LSD), 
AH-7921 (a synthetic opioid), MDPV (a synthetic cathinone derivative) and methoxetamine (an arylcyclohexylamine closely related to 
ketamine, marketed as its ‘legal’ alternative).
O
HN
H
N
4,4′-DMAR is a psycho-stimulant which has been available on the EU drug market since at 
least December 2012 and detected in nine Member States. In about 20 % of detections 
4,4′-DMAR was found in combination with other drugs (predominantly stimulants). It has 
been detected in 31 deaths in Hungary, Poland and the United Kingdom, over a 12-month 
period.
N N
MT-45 is a synthetic opioid, with analgesic potency similar to morphine, first detected in 
October 2013. It has been detected in 28 deaths, and 12 non-fatal intoxications in Sweden, 
over a nine-month period. In 19 of the deaths, MT-45 was either reported as the cause of 
death or contributing to death.
TABLE 1.1
New psychoactive substances risk-assessed in 2014
FIGURE 1.12
I  New substances risk-assessed in Europe in 2014
An EU mechanism exists for the identification, assessment 
and possible control of new psychoactive substances in 
Europe. In 2014, six new psychoactive substances were 
risk-assessed (see Table 1.1). These new drugs emerged in 
Europe in the past few years and have been linked to 
growing numbers of reports of harm, including 
hospitalisations and deaths. As of February 2015, four of 
the six substances have since been subjected to control 
measures throughout Europe.
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I Legal responses to evolving drug markets 
The rapid emergence of new psychoactive substances and 
the diversity of available products has proved challenging 
for Europe’s policymakers. At EU level, a surveillance 
system linked with a legal mechanism for control has 
existed since 1997 — the EU Early Warning System. This 
was strengthened in 2005. The current system has been 
reviewed and a proposal for a new legal framework is 
under discussion. 
At national level, a range of measures have been used to 
control new substances, and three broad types of legal 
response can be identified. In some countries, existing 
laws that cover issues unrelated to controlled drugs, such 
as consumer safety legislation, have been used; in others 
existing drug laws or processes have been extended or 
adapted; and in some countries new legislation has been 
designed. While there is wide variation in the definitions of 
the offences and the penalties, responses tend to focus on 
supply rather than possession of these substances.
I  The Internet: a marketplace for both new and established drugs
It has been recognised for some time that the Internet is 
an important marketplace for the sale of new psychoactive 
substances to Europeans. In 2013, an EMCDDA snapshot 
identified 651 websites selling ‘legal highs’ to Europeans, 
and targeted Internet snapshots carried out in 2014 
identified websites offering specific drugs such as the 
synthetic opioid MT-45 for sale, sometimes in kilogram 
quantities. 
The Internet and social media have also become 
increasingly important in the market for illicit drugs. 
Evidence is emerging of so-called grey marketplaces — 
online sites selling new psychoactive substances which 
operate on both the surface and the deep web. The deep 
web is part of the Internet that is not accessible using 
standard search engines. There, drug sales can take place 
within marketplaces, within decentralised networks and 
between individuals. Most attention has been received by 
drug cryptomarkets such as Silk Road, Evolution and 
Agora. These online markets are only accessible through 
the use of encryption software, which offers a high level of 
anonymity. Cryptomarkets, in common with online 
marketplaces such as eBay, provide sellers and buyers 
with an infrastructure to conduct transactions and 
services, such as seller and buyer ratings and hosting of 
discussion forums. Cryptocurrencies, like Bitcoin, are used 
to facilitate anonymous transactions, and stealth 
packaging is used to facilitate transportation of small 
quantities of drugs through established commercial 
channels. Among the various products advertised on 
cryptomarkets, established illicit drugs and prescribed 
medicines are reported to be the most commonly 
available. Evidence suggests that many illicit drug 
purchases made on the deep web are intended for resale.
Another development relates to drug supply and the 
sharing of drugs or drug experiences via social media, 
including mobile apps. This area remains both poorly 
understood and difficult to monitor. Together, the growth of 
online and virtual drug markets poses major challenges to 
law enforcement and drug control policies. The fact that 
manufacturers, suppliers, retailers, website-hosting and 
payment processing services may all be based in different 
countries makes online drug markets particularly difficult 
to control.
 The Internet is an important  
 marketplace for the sale  
 of new psychoactive  
 substances to Europeans 
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I  Responding to drug supply: common principles but differences in practice
Member States take measures to prevent the supply of 
illicit drugs under three United Nations Conventions, which 
provide an international framework for control of 
production, trade and possession of over 240 psychoactive 
substances. Each country is obliged to treat unauthorised 
supply as a criminal offence. The same is required for 
possession of drugs for personal use, but subject to a 
country’s ‘constitutional principles and the basic concepts 
of its legal system’. This clause has not been uniformly 
interpreted, and this is reflected in different legal 
approaches in European countries and elsewhere.
The implementation of laws to curb drug supply and use is 
monitored through data on reported drug law offences. 
Overall, the number of reported offences related to drug 
supply in Europe has been increasing since 2006. An 
estimated 230 000 supply offences were reported in 2013, 
most of which (57 %) related to cannabis. In the same year, 
of the estimated 1.1 million reported offences for drug use 
or possession for use, three-quarters (76 %) related to 
cannabis.
I  Wide variation in sentencing practice in Europe
Unauthorised drug supply is a crime in all European 
countries, but the penalties written in the law vary between 
states. In some countries, supply offences may be subject 
to a single wide penalty range (up to life in prison). Other 
countries differentiate between minor and major supply 
offences, determined by factors such as the quantity or 
type of drugs found, with corresponding maximum and 
minimum penalties. A recent EMCDDA case-scenario 
analysis found no clear relationship between the maximum 
penalties provided by the law and the sentences handed 
out by the courts. It also found that the penalties expected 
for drug trafficking offences varied between countries. For 
example, a first-time offender trafficking 1 kg of cannabis 
may expect a prison sentence varying from less than 
1 year in some countries to 10 years in others. Similarly, 
depending on the country, trafficking 1 kg of heroin could 
result in a penalty varying between 2 and 15 years. 
 Overall, the number  
 of reported offences related  
 to drug supply in Europe  
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I  Seizures and control of precursor chemicals
Drug precursors are chemicals that can be used in the 
manufacture of illicit drugs, and preventing their diversion 
from legitimate use is an important element in 
international efforts against illicit drug production. Most 
drug precursors have legitimate industrial uses, such as 
the production of plastics, medicinal products and 
cosmetics. For example, ephedrine — an ingredient in cold 
and decongestant medicines — may be used to produce 
methamphetamine. Due to their legitimate uses, 
production of and trade in precursor chemicals cannot be 
prohibited. Instead, drug precursors are controlled by 
monitoring their licit production and trade. 
Data from EU Member States on seizures and stopped 
shipments of drug precursors confirm the continued use of 
both scheduled and non-scheduled substances for the 
production of illicit drugs in the European Union (Table 1.2). 
In 2013, more than 48 000 kg of the pre-precursor APAAN 
(alpha-phenylacetoacetonitrile) was seized under national 
legislation, an amount sufficient to produce over 22 tonnes 
of amphetamine or methamphetamine. To increase the 
powers of law enforcement agencies to act on this 
substance, APAAN was scheduled as a precursor chemical 
under EU legislation in December 2013, and it was 
scheduled internationally in October 2014. Major seizures 
of precursors for MDMA confirm the return of large-scale 
ecstasy production to the European Union. In 2013, 
5 061 kg of PMK (3,4-methylenedioxyphenyl-2-propanone) 
and 13 837 litres of safrole were seized, which together 
would be capable of producing about 170 million 
ecstasy tablets.
New EU legislation was introduced in 2013 to strengthen 
controls over the trade in some drug precursors, both 
within the European Union and between Member States 
and third countries. Among the measures introduced are 
stricter controls on trade in acetic anhydride, a chemical 
needed to produce heroin, and in ephedrine and 
pseudoephedrine, precursors of methamphetamine. The 
new legislation also introduced a mechanism for rapid 
response to the diversion of non-scheduled substances.
Seizures Stopped shipments (1) TOTALS
Precursor/pre-precursor Cases Quantity Cases Quantity Cases Quantity
MDMA or related substances
PMK (litres) 12 5 061 0 0 12 5061
Safrole (litres) 4 13 837 1 574 5 14 411
Iso safrole (litres) 1 10 0 0 1 10
Piperonal (kg) 5 5 5 1 400 10 1 404
PMK glycidid/glycidate (kg) 5 2 077 0 0 5 2 077
Amphetamine and methamphetamine
BMK (litres) 5 32 0 0 5 32
PAA, phenylacetic acid (kg) 1 97 6 225 7 322
Ephedrine, bulk (kg) 15 13 0 0 15 13
Pseudoephedrine, bulk (kg) 11 64 0 0 11 64
APAAN (kg) 71 48 802 0 0 71 48 802
(1) A ‘stopped’ shipment is one that has been denied, suspended or voluntarily withdrawn by the exporter because of suspicion of diversion for illicit purposes.
Source: European Commission.
TABLE 1.2
Summary of seizures and stopped shipments of precursors used for selected synthetic drugs produced in Europe, 2013
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Chapter 2
In a top-level analysis of patterns and 
trends in drug use and their related 
harms, it is helpful to differentiate 
between three broad groups of 
substances: cannabis products, various 
stimulants and opioid drugs. The 
prevalence of cannabis use is about five 
times that of other substances, and the 
number of users entering treatment for 
cannabis problems has increased in 
recent years. While the use of heroin 
and other opioids remains relatively 
rare, these continue to be the drugs 
associated with most of the morbidity, 
mortality and cost of treatment related 
to drug use in Europe. 
Drug use is also characterised by different patterns of 
consumption, ranging from single experimental use to 
habitual and dependent use. Use of all drugs is generally 
higher among males, and this difference is often 
accentuated for more intensive or regular patterns of use. 
Different consumption patterns are also associated with 
different levels and types of harm; and more frequent use, 
high doses, concurrent use of several substances and 
injection are all linked to elevated health risks.
Drug use and 
drug-related problems
Monitoring drug use and drug-related 
problems
The EMCDDA’s five key epidemiological indicators 
are used as a basis for monitoring drug use and 
problems in Europe. These indicators incorporate 
data sets that cover estimates of recreational use 
(based mainly on surveys), estimates of high-risk 
use, drug-related deaths, infectious diseases and 
drug treatment entry. Taken together they provide the 
pillars supporting the European analysis of trends 
and developments in drug use and related harms. 
Technical information on the indicators can be found 
online in the Key indicators gateway and in the online 
Statistical Bulletin. In this chapter, data from the key 
indicators are complemented by additional data 
provided by Reitox focal points and other sources.
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I  Almost one in four Europeans have tried illicit drugs
Over 80 million adults, or almost a quarter of the adult 
population in the European Union, are estimated to have 
tried illicit drugs at some point in their lives. The most 
commonly used drug is cannabis (78.9 million), with lower 
estimates reported for the lifetime use of cocaine 
(15.6 million), amphetamines (12.0 million) and MDMA 
(12.3 million). Levels of lifetime use differ considerably 
between countries, ranging from around one-third of adults 
in Denmark, France and the United Kingdom, to 8 % or less 
than one in 10 in Bulgaria, Romania and Turkey.
I Cannabis use: rising in Nordic countries
Cannabis is the illicit drug most likely to be used by all age 
groups. The drug is generally smoked and, in Europe, is 
commonly mixed with tobacco. Patterns of cannabis use 
can range from the occasional to the regular and 
dependent. 
An estimated 14.6 million young Europeans (aged 15–34), 
or 11.7 % of this age group, used cannabis in the last year, 
with 8.8 million of these aged 15–24 (15.2 % of this 
age group). 
A number of countries have sufficient survey data to allow 
a statistical analysis of long-term time trends in last year 
cannabis use among young adults (15–34). Population 
surveys for Germany, Spain and the United Kingdom report 
decreasing or stable cannabis prevalence over the past 
decade. In contrast, increasing prevalence can be 
observed for Bulgaria, France and three of the Nordic 
countries, (Denmark, Finland, Sweden). In addition, 
Norway reported an increase to a new high of 12 % in its 
most recent survey, although the current time series is 
insufficient for a statistical analysis of trends. 
Taken as a whole, the most recent survey results continue 
to show divergent patterns in last year cannabis use 
(Figure 2.1). Of the countries that have produced surveys 
since 2012, four reported lower estimates, two were stable 
and eight reported higher estimates than in the previous 
comparable survey. Few national surveys currently report 
on the use of synthetic cannabinoids; for those that do, 
last year prevalence levels are generally low. 
FIGURE 2.1
Last year prevalence of cannabis use among young adults (15–34): 
most recent data (top) and countries with statistically significant 
trends (centre and bottom)
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I Cannabis use among school students
Monitoring substance use among students provides an 
important window on current youth risk behaviours. In 
Europe, the European School Survey Project on Alcohol 
and Other Drugs (ESPAD) study allows some insight into 
trends over time in substance use among 15- to 16-year-
old school students. In the last round of data collection 
(2011), cannabis accounted for the majority of illicit drug 
use in this group, with about 24 % reporting having ever 
used the drug, ranging from 5 % in Norway to 42 % in the 
Czech Republic. The prevalence of use of illicit drugs other 
than cannabis was far lower. 
In the seven countries that have reported national school 
surveys undertaken after the ESPAD study (2011), trends 
in prevalence of cannabis use among students show 
considerable variation.
I Concern about cannabis users
A minority of cannabis users consume the substance 
intensively. Daily or almost daily cannabis use is defined as 
use on 20 days or more in the last month. Based on 
surveys of the general population, it is estimated that 
almost 1 % of European adults are daily or almost daily 
cannabis users. Around three-quarters of these are aged 
between 15 and 34 years, and over three-quarters are 
male. 
While daily cannabis use is rare in the general population, 
among the nearly 3 % of adults (15–64) who used 
cannabis in the last month, around one-quarter used the 
substance daily or almost daily. This proportion varies 
substantially by country (see Figure 2.2). For the countries 
with a sufficient number of surveys to identify trends, the 
proportion of daily or almost daily users among all adults 
has remained stable over the last decade.
Cannabis is the drug most frequently reported as the 
principal reason for entering drug treatment by first-time 
clients in Europe, although what constitutes a treatment 
response for cannabis users varies considerably. The 
overall number of reported first-time treatment entrants 
rose from 45 000 to 61 000 between 2006 and 2013. 
Taking into account repeat entrants, cannabis was the 
second most frequently reported drug among all entrants 
to treatment in 2013 (123 000, 29 %). Considerable 
national variation exists, however, with reports of primary 
cannabis use ranging from 3 % of all treatment entrants in 
Lithuania to over 60 % in Denmark and Hungary. Various 
factors may contribute to this heterogeneity. For example, 
around one-quarter of those entering treatment in Europe 
for primary cannabis use are referred by the criminal 
justice system (23 000); this ranges from less than 5 % of 
primary cannabis clients in Bulgaria, Estonia, Latvia and 
the Netherlands to over 80 % in Hungary.
FIGURE 2.2
Proportion of last month cannabis users (15–64) who used the 
substance daily or almost daily
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I Hospital emergencies associated with cannabis
Although rare, acute emergencies can occur after 
consuming cannabis, especially at high doses. In countries 
with higher prevalence levels, cannabis accounts for a 
sizeable share of drug-related emergencies. A recent study 
identified an increase in the numbers of cannabis-related 
emergencies between 2008 and 2012 in 11 of the 13 
European countries analysed. In Spain, for example, the 
number of emergencies related to cannabis increased 
from 1 589 (25 % of all drug-related emergencies) in 2008 
to 1 980 (33 %) in 2011.
The European Drug Emergencies Network (Euro-DEN), 
which monitors drug-related emergency presentations in 
16 sites in 10 European countries, reported that between 
10 % and 48 % (16 % on average) of all drug-related 
presentations involved cannabis, although other 
substances were present in 90 % of these cases. Most 
commonly, cannabis was found alongside alcohol, 
benzodiazepines and stimulants. The most frequently 
reported problems were neuro-behavioural (agitation, 
aggression, psychosis and anxiety) and vomiting. In most 
cases, patients were discharged without the need for 
inpatient admission.
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I Cocaine: Europe’s most commonly used stimulant
Cocaine powder is primarily sniffed or snorted, but is also 
sometimes injected, while crack cocaine is usually 
smoked. Among regular users, a broad distinction can be 
made between more socially integrated consumers, who 
often sniff powder cocaine in a recreational context, and 
marginalised users, who inject cocaine or smoke crack 
often alongside the use of opioids. Regular cocaine use 
has been associated with dependence, cardiovascular, 
neurological and mental health problems, and with an 
elevated risk of accidents. Cocaine injection and use of 
crack cocaine are associated with the greatest health risks, 
including the transmission of infectious diseases.
Cocaine is the most commonly used illicit stimulant drug 
in Europe, although most users are found in a restricted 
number of countries. This is illustrated by survey data 
which show cocaine use to be more prevalent in the south 
and west of Europe. 
It is estimated that about 2.3 million young adults aged 15 
to 34 (1.9 % of this age group) used cocaine in the last 
year. Many cocaine users consume the drug recreationally, 
with use highest during weekends and holidays. Data from 
wastewater analysis carried out in a 2014 European 
multi-city study confirm daily differences in use. Higher 
concentrations of benzoylecgonine — the main metabolite 
of cocaine — were found in samples collected during the 
weekend (Figure 2.3). 
Only a few countries report last year prevalence of cocaine 
use among young adults of more than 3 % (Figure 2.4). 
Among these countries, Spain and the United Kingdom 
observed statistically significant increasing trends in 
prevalence until 2008, after which the trend changed to 
become stable or declining. Below 3 % prevalence, Ireland 
and Denmark report falls in the most recent data, but as 
yet this is not statistically discernible, while French surveys 
up until 2014 show an increasing trend in use.
FIGURE 2.3
Cocaine residues in wastewater: in selected European cities (left) and daily averages (right)
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Decreases in cocaine use are observable in the most 
recent data; of the countries that have produced surveys 
since 2012, eight reported lower estimates and three 
reported higher estimates than in the previous comparable 
survey.
I Continued decline in cocaine treatment demand
The prevalence of problematic forms of cocaine use in 
Europe is difficult to gauge as only four countries have 
recent estimates and, for methodological reasons, these 
are not easy to compare. In 2012, Germany estimated 
‘cocaine-dependency’ among the adult population at 
0.20 %. In 2013, Italy produced an estimate of 0.23 % for 
those ‘in need of treatment for cocaine use’, and Spain 
estimated ‘high-risk cocaine use’ at 0.29 %. For 2011/12, 
the United Kingdom estimated crack cocaine use among 
the adult population in England at 0.48 %, and the majority 
of these were also opioid users.
Cocaine was cited as the primary drug for 13 % of all 
reported clients entering specialised drug treatment in 
2013 (55 000), and 16 % of those entering treatment for 
the first time (25 000). Differences exist between 
countries, with more than 70 % of all cocaine clients being 
reported by only three countries (Spain, Italy, United 
Kingdom). In the most recent data, the number of cocaine 
clients entering treatment for the first time has stabilised 
at around 24 000; this number has declined from a peak of 
38 000 in 2008. In 2013, 6 000 clients entering treatment 
in Europe reported primary crack cocaine use, with the 
United Kingdom accounting for more than half of these 
(3 500), and Spain, France and the Netherlands most of 
the remainder (2 200).
Interpreting the available data on cocaine associated 
mortality is challenging, in part because this drug may be a 
factor in some deaths that are attributed to cardiovascular 
FIGURE 2.4
Last year prevalence of cocaine use among young adults (15–34): selected trends (left) and most recent data (right)
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 Over 800 deaths associated  
 with cocaine use were  
 reported in 2013 
problems. Nonetheless, over 800 deaths associated with 
cocaine use were reported in 2013 (data from 27 
countries). Most of these were attributed to drug overdose, 
with other substances also being detected in many cases, 
primarily opioids. At the European level, data quality issues 
mean that it is not possible to comment on trends. Some 
countries, however, do have limited information available. 
For example, between 2012 and 2013, the number of 
deaths in which the presence of cocaine was recorded 
increased from 174 to 215 in the United Kingdom and 
from 19 to 29 in Turkey.
I Amphetamines: use stable in many countries
Amphetamine and methamphetamine, two closely related 
stimulants, are both consumed in Europe, although 
amphetamine is by far the more commonly used. 
Methamphetamine consumption has historically been 
restricted to the Czech Republic and, more recently, 
Slovakia, although there are now signs of growing use in 
other countries. In some data sets, it is not possible to 
distinguish between these two substances; in these cases, 
the generic term amphetamines is used.
Both drugs can be taken orally or nasally; in addition, 
injection is common among high-risk users in some 
countries. Methamphetamine can also be smoked, but this 
route of administration is not commonly reported in 
Europe.
Adverse health effects linked with amphetamines use 
include cardiovascular, pulmonary, neurological and 
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mental health problems, while as with other drugs, 
injection is a risk factor for infectious diseases. As with 
other stimulants, deaths related to amphetamines can be 
difficult to identify. However, small numbers are reported 
annually. 
An estimated 1.3 million (1.0 %) young adults (15–34) 
used amphetamines during the last year. The most recent 
national prevalence estimates range from 0.1 % to 1.8 % 
(Figure 2.5). The data available suggest that from around 
2000, most European countries have experienced a 
relatively stable situation in respect to trends in use. 
Exceptions here are Spain and the United Kingdom, where 
a statistically significant decrease in prevalence can be 
observed since 2000.
I New patterns in problem amphetamines use
In respect to long-term, chronic and injecting 
amphetamine use, historically, problems have mostly been 
observed in northern European countries. In contrast, 
long-term methamphetamine problems have been most 
apparent in the Czech Republic and Slovakia. These 
countries report estimates of problem use among adults 
(15–64) at around 0.48 % for the Czech Republic (2013) 
and 0.21 % in Slovakia (2007). In the Czech Republic, a 
marked increase in problem or high-risk 
methamphetamine use, mainly injection, has been 
observed between 2007 and 2013 (from around 20 000 to 
over 34 000). There are recent indications that 
methamphetamine use is diffusing to other countries and 
new populations, with the use of the drug being reported in 
FIGURE 2.5
Last year prevalence of amphetamines use among young adults (15–34): selected trends (left) and most recent data (right)
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countries bordering the Czech Republic (Germany, Austria) 
in parts of southern Europe (Greece, Cyprus, Turkey) and 
in northern European countries (Latvia, Norway). A new 
pattern of methamphetamine use continues to be reported 
in a number of European countries, where the drug is 
injected, often alongside other stimulants, among small 
groups of men who have sex with men. These so-called 
slamming parties are a concern because of the 
combination of risk-taking in both drug-use and sexual 
behaviours. 
Around 7 % of clients entering specialised drug treatment 
in Europe in 2013 report amphetamines (amphetamine 
and methamphetamine) as their primary drug. This 
amounts to approximately 29 000 clients, of whom 12 000 
entered treatment for the first time in their life. Primary 
amphetamine users account for a sizeable proportion of 
reported first-time treatment entries in only Germany, 
Latvia and Poland. Treatment entrants reporting primary 
methamphetamine use are concentrated in the Czech 
Republic and Slovakia, which together account for 95 % of 
the 8 000 methamphetamine clients in Europe. Increases 
in first-time entrants for amphetamines are accounted for 
primarily by Germany, the Czech Republic and Slovakia. 
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I MDMA/ecstasy use
MDMA (3,4-methylenedioxy-methamphetamine) is 
commonly used in the form of ecstasy tablets, but is now 
also increasingly available as crystals and powders; tablets 
are usually swallowed, but in powder form the drug is also 
snorted (nasal insufflation). Problems associated with use 
of this drug include acute hyperthermia, increased heart 
rate and multi-organ failure, and long-term use has been 
linked with liver and heart problems. Deaths associated 
with this drug remain relatively rare, and are sometimes 
caused by other substances sold as MDMA. There have 
been recent concerns about acute problems linked with 
high-dose MDMA tablets and powders. In addition, 
warnings have been issued in 2014 about ecstasy tablets 
that contained high concentrations of PMMA — a drug 
with a worrying safety profile.
Most European surveys have historically collected data on 
ecstasy rather than MDMA use. It is estimated that 
1.8 million young adults (15–34) used ecstasy in the last 
year (1.4 % of this age group), with national estimates 
ranging from under 0.1 % to 3.1 %. Among those countries 
with sufficient data to explore trends statistically, 
decreasing prevalence can be observed since 2000 in 
Germany, Spain and the United Kingdom. Denmark has a 
similar pattern of decreasing prevalence, but at a lower 
level of statistical certainty (Figure 2.6). In contrast, a 
pattern of increasing prevalence estimates continues in 
Bulgaria. Among the countries that have produced new 
surveys since 2012 results diverge: six reported lower 
prevalence estimates and seven reported higher estimates 
than in the previous comparable survey. Ecstasy use is 
rarely reported as a reason for entering drug treatment, with 
the drug being responsible for less than 1 % (around 600 
cases) of reported first-time treatment entrants in 2013.
FIGURE 2.6
Last year prevalence of ecstasy use among young adults (15–34): selected trends (left) and most recent data (right)
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I  GHB, ketamine and hallucinogens: still causing concern in some countries
A number of other psychoactive substances with 
hallucinogenic, anaesthetic and depressant properties are 
used in Europe: these include LSD (lysergic acid 
diethylamide), ketamine, GHB (gamma-hydroxybutyrate) 
and hallucinogenic mushrooms. 
The recreational use of ketamine and GHB (including its 
precursor GBL, gamma-butyrolactone) has been reported 
among subgroups of drug users in Europe for the last two 
decades. There is growing recognition of the health 
problems related to these substances, for example, 
damage to the bladder associated with long-term 
ketamine use. Loss of consciousness, withdrawal 
syndrome and dependence are risks linked to use of GHB. 
Treatment requests related to GHB are reported in 
Belgium, the Netherlands and the United Kingdom. 
Where they exist, national estimates of the prevalence of 
GHB and ketamine use in both adult and school 
populations remain low. In their most recent surveys, 
Norway reported last year prevalence of GHB use at 0.1 % 
for adults (15–64), while Denmark and Spain reported last 
year prevalence of ketamine use at 0.3 % among young 
adults (15–34), and the United Kingdom reported last year 
ketamine use at 1.8 % among 16- to 24-year-olds, a stable 
trend since 2008. 
The overall prevalence levels of hallucinogenic mushrooms 
and LSD use in Europe have been generally low and stable 
for a number of years. Among young adults (15–34), 
national surveys report last year prevalence estimates of 
under 1 % for both substances.
I Higher levels of drug use among nightclub goers
It is well known that some social settings are particularly 
associated with elevated levels of drug and alcohol 
consumption. Typically, surveys of young people who 
regularly attend nightlife events indicate higher levels of 
drug use compared with the general population. This can 
been seen in information from the Internet-based Global 
Drug Survey, where the EMCDDA has commissioned a 
special analysis of drug use among young adults who 
self-identified as regular nightclub goers (defined as 
attending at least every three months). Analysis was 
performed on a sample of 25 790 young people aged 
15–34, from 10 European countries. It should be noted 
that this is a non-representative, self-selected sample who 
responded to an online drug survey, and therefore the 
results must be interpreted with caution. Among this 
sample, depending on the substance, last year prevalence 
was between 4 and nearly 25 times higher than that found 
among the same age group in the general population of 
the European Union. Grouping together the available 
countries for each drug and comparing with the weighted 
average from general population surveys (GPS), around 
55 % of the regular club-goers reported last year use of 
cannabis (GPS weighted country average 12.9 %), with 
high figures for other drugs: cocaine 22 % (GPS 2.4 %); 
amphetamines 19 % (GPS 1.2 %); ecstasy 37 % (GPS 
1.5 %) (Figure 2.7). Last year prevalence levels among the 
club-goers were also reported for other drugs, including 
ketamine (11 %), mephedrone (3 %), synthetic 
cannabinoids (3 %) and GHB (2 %).
A small number of club-goers reported experiencing 
problems with their drug use, with cannabis and ecstasy 
the drugs most commonly associated with acute 
emergency presentations among this group.
I Use of ‘legal highs’ among young people
The prevalence of use of new psychoactive substances in 
Europe is hard to ascertain. Where these substances are 
incorporated in national surveys, the lack of a common 
methodology means that the data are rarely comparable 
between countries, and definitional problems complicate 
things further, especially as the legal status of substances 
can change rapidly. Nevertheless, some insights into use of 
these substances is provided by the 2014 Flash 
Eurobarometer on young people and drugs, a telephone 
survey of 13 128 young adults aged 15–24 in the 28 EU 
Member States. In response to a question on perceived 
FIGURE 2.7
Last year prevalence among young adults (15–34): general 
population and club-goers (10 countries)
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availability, over two-thirds of respondents thought it would 
be difficult or impossible to obtain ‘legal highs’ — defined 
as new substances that imitate the effects of illicit drugs. 
Although primarily an attitudinal survey, the Eurobarometer 
included a question on the use of ‘legal highs’. Currently, 
these data represent the only EU-wide information source 
on this topic, although for methodological reasons caution 
is required in interpreting the results. Overall, 8 % of 
respondents reported lifetime use of ‘legal highs’, with 3 % 
reporting use in the last year (Figure 2.8). This represents 
an increase from the 5 % reporting lifetime use in a similar 
survey in 2011. The highest levels of use in the last year 
were reported by young people from Ireland (9 %), while 
use of ‘legal highs’ in the last year was not reported in the 
samples from Cyprus and Malta. Of those reporting use in 
the last year, 68 % had obtained the substance from a 
friend.
It is of interest to consider the Eurobarometer results 
alongside those from other surveys, while noting that 
different methods and questions are being employed. Nine 
European countries have reported national estimates of 
the use of new psychoactive substances or ‘legal highs’ 
(not including ketamine and GHB), since 2011. Last year 
prevalence of use of these substances among young 
adults (aged 15–24) ranges from 9.7 % in Ireland to 0.2 % 
in Portugal. It should be noted that in both of these 
countries, measures have been introduced to restrict the 
direct availability of ‘legal highs’ by closing shops where 
these products were being sold. Survey data for the United 
Kingdom (England and Wales) are available on the use of 
mephedrone. In the most recent survey (2013/14), last 
year use of this drug among young people aged 16 to 24 
was estimated at 1.9 %; this figure was stable compared 
with the previous year, but down from 4.4 % in 2010/11, 
before control measures were introduced.
The injection of synthetic cathinones, although not a 
widespread phenomenon, continues to be reported in 
some specific populations, including opioid injectors, drug 
treatment clients in some countries and small populations 
of men who have sex with men. An increase in treatment 
demand associated with synthetic cathinone use problems 
has been reported in Hungary, Romania and the United 
Kingdom. In the United Kingdom (England), the number of 
first-time treatment entrants reporting any use of 
mephedrone increased from 900 to 1 630 between 
2011/12 and 2012/13, with numbers stabilising in 
2013/14 at 1 641.
FIGURE 2.8
Availability and use of ‘legal highs’, defined as new substances that imitate the effects of illicit drugs
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I Opioids: 1.3 million problem users
The illicit use of opioids remains responsible for a 
disproportionately large share of the morbidity and 
mortality resulting from drug use in Europe. The main 
opioid used in Europe is heroin, which may be smoked, 
snorted or injected. A range of other synthetic opioids, 
such as buprenorphine, methadone and fentanyl, are also 
misused. 
The average annual prevalence of high-risk opioid use 
among adults (15–64) is estimated at around 0.4 % (4 per 
1 000 population), the equivalent of 1.3 million problem 
opioid users in Europe in 2013. Prevalence estimates of 
high-risk opioid use vary between countries from less than 
one to around eight cases per 1 000 population aged 
15–64. Ten countries have repeated estimates of high-risk 
opioid use between 2006 and 2013 and these show 
relatively stable trends (Figure 2.9).
Clients using opioids, mainly heroin, as their primary drug 
represent 41 % of all drug users who entered specialised 
treatment in 2013 in Europe (175 000 clients), and 20 % of 
those entering treatment for the first time (31 000 clients). 
The number of new heroin clients has more than halved 
from a peak of 59 000 in 2007 to 23 000 in 2013. Overall, 
it appears likely that recruitment into heroin use has 
decreased and that this is now impacting on treatment 
demand.
I Opioids other than heroin: of increasing concern
In just over a third (11) of European countries, more than 
10 % of all opioid clients entering specialised services in 
2013 were treated for problems primarily related to opioids 
other than heroin (Figure 2.10). These substances include 
methadone, buprenorphine and fentanyl. Overall, misused 
methadone is the most commonly reported opioid other 
than heroin, followed by buprenorphine; respectively, these 
drugs account for 60 % and 30 % of all treatment demands 
from clients whose primary drug problem relates to opioids 
other than heroin. In some countries, other opioids now 
represent the most common form of problem opioid use. In 
Estonia, for example, the majority of treatment entrants 
reporting an opioid as their primary drug were using illicit 
fentanyl, while in Finland most opioid clients are reported 
to be primary misusers of buprenorphine.
FIGURE 2.9
National estimates of last year prevalence of high-risk opioid use: trends (left) and most recent data (right)
 The main opioid used  
 in Europe is heroin 
0.0–2.5 2.51–5.0 >5.0 No dataRate per 1 000
Malta Latvia Austria Italy
Germany Greece
Czech Republic Turkey
Spain Cyprus
Cases per 1 000 population aged 15–64
2007 2008 2009 2011 2013
8
7
4
5
6
3
2
1
0
8
7
4
5
6
3
2
1
0
20122010
52
European Drug Report 2015: Trends and Developments
I High-risk opioid users: an ageing population
Two trends are evident among opioid users entering 
treatment: their numbers are declining and the average 
age is increasing (Figure 2.11). Between 2006 and 2013, 
the median age of clients entering treatment for problems 
related to opioid use increased by 5 years. During the 
same period, the average age of drug-induced deaths 
(which are mainly related to opioids) increased from 33 to 
37 years. A significant number of problem opioid users in 
Europe with long-term polydrug use histories are now aged 
in their 40s and 50s. A history of poor health, bad living 
conditions, tobacco and alcohol use, and age-related 
deterioration of the immune system make these users 
susceptible to a range of chronic health problems. Among 
these are cardiovascular and lung problems resulting from 
chronic tobacco use and injecting drug use. Long-term 
heroin users are also reporting chronic pain conditions, 
while infection with hepatitis virus can place them at 
increased risk of cirrhosis and other liver problems. The 
cumulative effects of polydrug use, overdose and 
infections over many years accelerate physical ageing 
among these users, with growing implications for 
treatment and social support services.
FIGURE 2.10
Treatment entrants citing opioids as primary drug: by type of opioid (left) and percentage reporting opioids other than heroin (right)
FIGURE 2.11
Trends in age structure of clients entering treatment by primary 
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I Injecting drug use: long-term decline 
Injecting drug users are among those at highest risk of 
experiencing harms from their drug use, including blood-
borne infections or drug overdoses. Injection is most 
commonly associated with opioid use, although in a few 
countries, amphetamines injection is a major problem. 
Recent estimates of the prevalence of injecting drug use 
are available for 14 countries, where they range from less 
than one to more than nine cases per 1 000 population 
aged 15–64. 
Among those entering specialised treatment for the first 
time with amphetamines as their primary drug, 46 % report 
injecting as their main route of administration, with a 
stable overall trend (Figure 2.12). Each year, over 70 % of 
these are reported by the Czech Republic, where the trend 
has been increasing. For the remaining European 
countries, injecting as the main route of administration for 
new amphetamine clients is in decline. Among first-time 
clients reporting heroin as their primary drug, 33 % 
reported injecting as their main route of administration, 
down from 43 % in 2006. Levels of injecting among heroin 
clients vary between countries, from 8 % in the 
Netherlands to 100 % in Lithuania. Taking the main three 
injected drugs together, among first-time entrants to 
treatment in Europe, injecting as the main route of 
administration has declined from 28 % in 2006 to 20 % 
in 2013.
FIGURE 2.12
First-time treatment entrants reporting injecting as the main route 
of administration of their primary drug
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I  New HIV cases among injectors fall as Greece curbs outbreak
Drug injection continues to play a central role in the 
transmission of blood-borne infections such as the 
hepatitis C virus (HCV) and, in some countries, the human 
immunodeficiency virus (HIV). Among all HIV cases notified 
in Europe where the route of transmission is known, the 
percentage attributable to injecting drug use has remained 
low and stable (under 8 % for the last decade).
The latest figures show that the increase in the number of 
new HIV diagnoses in Europe, which resulted from 
outbreaks in Greece and Romania, has halted and the EU 
total has dropped to pre-outbreak levels (Figure 2.13). 
Provisional figures for 2013 show 1 458 newly reported 
cases, compared with 1 974 in 2012, reversing the upward 
trend observed since 2010. This drop is largely explained 
by decreases in Greece, where the number of new cases 
more than halved from 2012 to 2013, and to a lesser 
extent, Romania. Although the outbreaks seem to have 
peaked in these two countries, the number of new 
diagnoses in 2013 remains at least 10 times higher than 
the pre-outbreak level in 2010.
In 2013, the average rate of newly reported HIV diagnoses 
attributed to injecting drug use was 2.5 per million 
population, with the three Baltic States showing rates 8 to 
22 times higher than the EU average. In other countries 
FIGURE 2.13
Newly diagnosed HIV cases related to injecting drug use: trends in number of cases (left) and most recent data (right)
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Data for 2013 (source: ECDC).
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that have experienced periods with high rates of infection 
in the past, such as Spain and Portugal, rates of newly 
reported diagnoses continue to decline. 
Early diagnosis and prompt appropriate treatment are 
important in preventing progression from HIV infection to 
AIDS. In 2013, there were 769 notifications of new AIDS 
cases in Europe attributable to injecting drug use. The 
relatively high numbers of new diagnoses coming from 
Bulgaria, Latvia, Greece and Romania suggests that AIDS 
prevention and HIV treatment responses in these countries 
require strengthening. 
HIV-related mortality is one of the best documented 
indirect causes of death among drug users. The most 
recent estimate suggests that about 1 700 people died of 
HIV/AIDS attributable to injecting drug use in Europe in 
2010, and the trend is downward.
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I  Hepatitis and other infections associated with drug use
Viral hepatitis, particularly infection caused by the hepatitis 
C virus (HCV), is highly prevalent among injecting drug 
users across Europe. This may have important long-term 
consequences, as HCV infection, often worsened by heavy 
alcohol use, is likely to account for increasing numbers of 
cases of cirrhosis, liver cancer and death among injecting 
drug users.
HCV antibody levels among national samples of injecting 
drug users in 2012–13 varied from 14 % to 84 %, with 5 of 
the 10 countries with national data reporting a prevalence 
rate in excess of 50 % (Figure 2.14). Among countries with 
national trend data for the period 2006–13, declining HCV 
prevalence in injecting drug users was only reported in 
Norway, while six other countries observed an increase. 
Drug use may be a risk factor for other infectious diseases 
including hepatitis A and B, sexually transmitted diseases, 
tuberculosis, tetanus and botulism. Sporadic cases of 
wound botulism among injecting drug users have been 
reported in Europe. In Norway, six confirmed cases were 
reported between September and November 2013. Two 
clusters of wound botulism cases — in Norway and 
Scotland — were identified in December 2014, and these 
were under investigation into 2015.
FIGURE 2.14
HCV antibody prevalence among injecting drug users, 2012/2013
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I Drug-related deaths
Drug use is one of the major causes of avoidable mortality 
among young people in Europe, both directly through 
overdose (drug-induced deaths) and indirectly through 
drug-related diseases, accidents, violence and suicide. 
Most studies on cohorts of problem drug users show 
mortality rates in the range of 1–2 % per year, and it has 
been estimated that between 10 000 and 20 000 opioid 
users die each year in Europe. Overall, opioid users are at 
least 10 times more likely to die than their peers of the 
same age and gender. A recent EMCDDA multisite study 
with data from nine European countries found that most 
deaths among problem drug users are premature and 
preventable. The study recorded 2 886 deaths among a 
sample of over 31 000 participants, with an overall annual 
mortality rate of 14.2 per 1 000. Cause of death was 
identified for 71 % of the cases, and half of these deaths 
were accounted for by external causes, mostly overdose 
and to a lesser extent suicide, and the other half were 
attributed to somatic causes including HIV/AIDS, and 
circulatory and respiratory diseases.
I  Overdose deaths: recent increases in some countries
Overall, drug overdose continues to be the main cause of 
death among problem drug users, and over three-quarters 
of overdose victims are male (78 %). While it is often the 
deaths among the very young that generate concern, only 
8 % of the overdose deaths reported in Europe in 2013 
were aged under 25 years. Between 2006 and 2013, a 
pattern can be observed of decreasing numbers of 
overdose deaths among younger drug users and 
increasing numbers among older users (Figure 2.15). This 
reflects the ageing nature of Europe’s opioid-using 
population, who are at greatest risk of drug overdose 
death. 
Most countries reported an increasing trend in overdose 
deaths from 2003 until around 2008/09, when overall 
levels first stabilised and then began to decline. Caution is 
required when interpreting overdose data, and especially 
the EU cumulative total, for a number of reasons, which 
include systematic under-reporting in some countries and 
registration processes that result in reporting delays, both 
for cases and national totals. Because of these delays, the 
EU total for the current year is a provisional value which is 
subject to revision as new data become available. The EU 
estimate for 2013 is a minimum of 6 100 deaths. This is a 
slight increase from the revised 2012 figure. It is of 
FIGURE 2.15
Number of drug-induced deaths by age group in 2006 and in 2013
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particular concern that increases are evident in the most 
recent data from a number of countries with relatively 
robust reporting systems, including Germany, Sweden and 
the United Kingdom. Turkey is also showing increases, but 
this may partly reflect improved reporting. 
Heroin or its metabolites are present in the majority of fatal 
overdoses reported in Europe, often in combination with 
other substances. In the United Kingdom (England) and 
Turkey, increases in reported deaths are driven to a large 
extent by deaths where heroin is implicated. In addition to 
heroin, other opioids including methadone, buprenorphine, 
fentanyls and tramadol are regularly found in toxicological 
reports, and these substances are now associated with a 
substantial share of overdose deaths in some countries. 
For 2013, the average mortality rate due to overdoses in 
Europe is estimated at 16 deaths per million population 
aged 15–64. National mortality rates vary considerably and 
are influenced by factors such as prevalence and patterns 
of drug use, particularly injecting and opioid use, the 
characteristics of drug-using populations, the availability 
and purity of the drugs, reporting practices and provision 
of services. Rates of over 40 deaths per million were 
reported in seven countries, with the highest rates reported 
in Estonia (127 per million), Norway (70 per million) and 
Sweden (70 per million) (Figure 2.16). Although national 
differences in coding and reporting practices, as well as 
possible under-reporting, make it difficult to compare 
countries, analysing trends over time within individual 
countries is valuable. Recent improvements have been 
observed in the mortality rate due to overdose in Estonia, 
although the rates still remain eight times higher than the 
EU average. Overdose deaths there are mostly related to 
the injection of fentanyls — highly potent opioids.
FIGURE 2.16
Drug-induced mortality rates among adults (15–64): selected trends (left) and most recent data (right)
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I  New drugs: increasingly linked with drug-related harms and deaths
Overall, there is increasing evidence of the role that new 
psychoactive substances play in hospital emergencies and 
some drug-induced deaths in Europe. In 2014, the EU 
Early Warning System issued 16 alerts in relation to new 
substances being monitored by the mechanism, with many 
concerning serious adverse events such as deaths. A 
recent analysis by the European Drug Emergencies 
Network, which monitors emergency presentations in sites 
in 10 European countries, found that 9 % of all drug-
related emergencies involved new psychoactive 
substances, primarily cathinones. In addition, 12 % of all 
presentations were for GHB or GBL and 2 % were for 
ketamine. 
Recent reports of acute adverse health consequences 
associated with synthetic cannabinoids indicate that use 
of these substances may in some circumstances result in 
serious health consequences, including mortality. A 2015 
review reported the most common adverse health effects 
associated with synthetic cannabinoids to be tachycardia, 
extreme agitation and hallucinations.
Evaluating the toxicological significance of any substance 
in a death is often complicated, especially given that in 
most drug-induced deaths multiple substances will have 
been consumed. These problems are accentuated for new 
drugs, which may be difficult to detect and not be included 
in commonly used screening tools. Despite these 
limitations, some data are available. In Hungary, for 
example, new psychoactive substances were detected in 
around half of the reported drug-induced deaths in 2013 
(14 out of 31 cases), all in the presence of other 
substances. Case reports are also collected by the Early 
Warning System as part of the risk assessment of new 
drugs. These data indicate the role some new psychoactive 
substances can play in drug-related morbidity and 
mortality: for example, the synthetic cathinone MDPV, 
which was first detected in 2008, had been found in 99 
deaths at the time of its risk assessment in 2014.
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Chapter 3
In this chapter, policies and 
interventions designed to prevent, treat 
and reduce harms related to drug use 
are reviewed. The focus is on the extent 
to which countries have adopted 
common approaches, which of these 
are informed by evidence, and whether 
service provision matches estimated 
need. The key policy areas monitored at 
European level include national drug 
strategies and action plans, drug-
related budgets and public expenditure 
estimates.
Monitoring health and social responses
Data used here are provided by Reitox focal points 
and expert working groups, complemented by reports 
on treatment demands, opioid substitution treatment 
and needle and syringe provision. Expert ratings 
provide supplementary information on the availability 
of services, where more formalised datasets are 
unavailable. The chapter is also informed by reviews 
of the scientific evidence on the effectiveness of 
public health interventions. 
Supporting information can be found on the 
EMCDDA website in the Health and social responses 
profiles, the Statistical Bulletin, the Best practice 
portal and under European drug policy and law.
I National and city level drug strategies
The European Drugs strategy 2013–20 and accompanying 
action plans provide a framework for coordinated 
responses to drug problems in Europe. At the country level, 
this is mirrored in national drug strategies, budgetary 
frameworks and plans. These time-limited documents 
usually contain a set of general principles, objectives and 
priorities, specifying actions and the parties responsible 
for their implementation. All countries have now a national 
drug policy and, in all but two countries, this can be found 
in a national drug strategy document. The exceptions are 
Austria, where drug strategy is included in regional plans, 
and Denmark, where the issue is addressed in a number of 
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policy documents and actions. National strategies and 
action plans that cover both licit and illicit drugs have been 
adopted by eight countries (Figure 3.1). Evaluation of drug 
strategies and action plans has been conducted in many 
countries. The aim of evaluation is generally to assess the 
changes in the overall drug situation as well as the level of 
implementation achieved.
City authorities in Europe are often responsible for 
coordinating local drug policy, in some instances with 
dedicated budgets. In many countries, strategic planning 
documents also exist to support policy implementation. 
A recent EMCDDA study reported on 10 capital cities with 
a dedicated drugs strategy, and in some cases an 
accompanying action plan. Some of these had broad 
coverage, while others focused on a specific issue such as 
overdose deaths, use of GHB or problems linked to open 
drug scenes. In some cities without a specific drug 
strategy, drug policy objectives were incorporated into 
wider local health or crime reduction strategies. In others, 
drug issues were covered by broader regional or national 
policy documents.
I  Austerity impacts on funding for health interventions
The information available on drug-related public 
expenditure in Europe, at both local and national level, 
remains sparse and heterogeneous. For the 18 countries 
that have produced estimates in the past 10 years, 
drug-related public expenditure is estimated at between 
0.01 % and 0.5 % of gross domestic product, with health 
interventions representing between 24 % and 73 % of total 
drug-related expenditure. Differences in the scope and 
quality of the estimates make it difficult to compare 
drug-related public expenditure between countries. 
In the wake of the 2008 economic recession, many 
European governments imposed fiscal consolidation 
measures, often referred to as austerity measures. The size 
of the economic downturn, its impact and the timing and 
the scale of fiscal measures varied markedly between 
countries. In many countries, austerity measures led to 
reductions in public spending in those categories of 
government activity that encompass the bulk of drug-
related initiatives. Analysis carried out by the EMCDDA 
suggests that overall, bigger cuts were more often 
registered in the health sector than in other areas such as 
public order and safety or social protection. Data for the 
period 2009–12 show a decline in public spending on 
health in most countries, compared with the pre-recession 
period 2005–07, with reductions of more than 
10 percentage points in many European countries, at 
constant prices (Figure 3.2). As drug-related health 
expenditure represents a small proportion of total public 
health spending (often less than 1 %), trends in drug-
related funding cannot be directly inferred from this data. 
Nevertheless, reductions in health funding are likely to 
have a negative impact on drug-related initiatives and 
EMCDDA reporting suggests that funding of drug-related 
research and prevention activities may have been 
particularly affected.
FIGURE 3.1
National drug strategies and action plans: availability and scope
Combined licit and illicit drug strategy
No national drug strategyIllicit drug strategy
NB:  While the United Kingdom has an illicit drug strategy, both Wales and 
Northern Ireland have combined strategies which include alcohol.
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I Prevention of drug use among young people
The prevention of drug use and drug-related problems 
among young people is a key policy objective and is one of 
the pillars of the European Drugs Strategy 2013–20. Drug 
prevention encompasses a wide range of approaches. 
Environmental and universal strategies target entire 
populations, selective prevention targets vulnerable groups 
who may be at greater risk of developing drug use 
problems, and indicated prevention focuses on at-risk 
individuals. Over the last decade, the availability of quality 
standards, which can support intervention delivery and 
best practice, has grown. The European Drug Prevention 
Quality Standards Project provides toolkits to support the 
implementation of standards in this area.
A relatively robust evidence base exists for some 
prevention approaches that may be implemented in school 
settings. While countries report extensive implementation 
of smoking bans in schools and school drug policies, 
approaches for which an evidence base exists, prevention 
approaches solely based on the provision of information 
are also reported to be quite widely available (Figure 3.3). 
Providing health-related information may be important in 
educational terms, however, there is little evidence 
available to suggest that this form of prevention impacts 
on future drug-taking behaviour. 
Early detection and intervention approaches are used in 
some schools, often based on the provision of counselling 
to young substance users. A Canadian programme 
(Preventure) that targets young sensation-seeking drinkers 
has been positively evaluated; it has been adapted for use 
in the Czech Republic, the Netherlands and the United 
Kingdom. 
With regard to the provision of prevention interventions to 
specific vulnerable groups, the approaches with the 
highest availability are reported to be those targeting 
families with substance misuse problems, the provision of 
interventions for pupils with social and academic problems 
and interventions for young offenders. One programme of 
note targeting young offenders is FreD, a set of manual-
based interventions, which has been implemented in 15 
EU Member States. Evaluations of this programme have 
shown a fall in repeat-offending rates.
FIGURE 3.2
Estimated accumulated growth of public expenditure on health 
(2005–07 and 2009–12), at constant prices
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I New drugs and new challenges
In European countries, initial responses to the emergence 
of new psychoactive substances have been predominantly 
regulatory in nature, focused on tackling their supply using 
legislative tools. Increasingly, however, more attention is 
being paid to the development of targeted education and 
prevention activities, as well as training and awareness-
raising activities for professionals. In addition, services 
working in nightlife and recreational settings have tended 
to integrate their response to new substances within 
established approaches. The Internet is also increasingly 
important as a platform for the provision of information 
and counselling. One development has been the use of 
‘online-outreach’ interventions to reach the new target 
groups. Examples include drug user-led initiatives, such as 
forums and blogs, which provide consumer protection 
information and advice. In a few cases, these interventions 
have been linked with drug testing and pill-checking 
services, with results and harm reduction messages 
disseminated online. 
Currently, in Europe, new psychoactive substances are not 
associated with a significant demand for specialist 
treatment, although service developments are now seen in 
some countries. The emergence of new drugs has 
manifested itself in different ways in individual countries, 
and national responses reflect these differences. In 
Hungary and Romania, where the injecting of cathinones 
has been reported, needle and syringe exchange services 
play an important role. In the United Kingdom, where 
significant use of mephedrone has been recorded, 
specialist ‘club-drug clinics’ are engaging with this client 
group and treatment guidelines are being developed.
FIGURE 3.3
School-based interventions to prevent substance use: provision and evidence of effectiveness 
(European averages based on expert ratings, 2013)
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NB: Evidence statements are based on the EMCDDA Best practice portal and UNODC evidence standards.
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I  Most drug treatment provided in outpatient settings
Most drug treatment in Europe is provided in outpatient 
settings, with specialised outpatient centres representing 
the largest provider in terms of drug users reached, 
followed by general healthcare centres (Figure 3.4). These 
include general practitioners’ surgeries, reflecting their role 
as prescribers of opioid substitution treatment in some 
large countries, such as Germany and France. A sizeable 
proportion of drug treatment in Europe is also provided in 
inpatient settings, such as hospital-based residential 
centres (e.g. psychiatric hospitals), therapeutic 
communities and specialised residential treatment 
centres. The relative importance of outpatient and 
inpatient provision within national treatment systems 
varies greatly between countries. In addition, many 
countries have low-threshold services, and although many 
of these do not provide structured treatment, in some 
countries, like France and the Czech Republic, these 
agencies are considered as an integral part of the national 
treatment system.
An estimated 1.6 million people received treatment for 
illicit drug use in Europe (1.4 million in the European 
Union) during 2013. This number is 0.3 million above the 
2012 estimate. The increase is in part due to improved 
reporting methods and new data, in particular the 
inclusion of 200 000 outpatient clients from Turkey. 
Data from monitoring treatment entries show that after 
opioids, cannabis and cocaine users are the second and 
third largest groups entering specialised drug treatment 
services (Figure 3.5). Psychosocial interventions are the 
main treatment modality used with these clients.
FIGURE 3.4 FIGURE 3.5
Numbers receiving drug treatment in Europe in 2013, by setting Trends in percentage of clients entering specialised drug treatment 
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I  Opioid substitution treatment: the most common modality, but numbers decreasing
Opioid users represent the largest group undergoing 
specialised treatment in Europe and consume the greatest 
share of available treatment resources. Substitution 
treatment, typically combined with psychosocial 
interventions, is the most common treatment for opioid 
dependence. This approach is supported by the available 
evidence, with positive outcomes found in respect to 
treatment retention, reduced illicit opioid use, reported risk 
behaviour, and reductions in drug-related harms and 
mortality. 
Methadone is the most commonly prescribed opioid 
substitution medication, received by over two-thirds (69 %) 
of substitution clients. A further 28 % of clients are treated 
with buprenorphine, which is the principal substitution 
medication used in six countries. Other substances, such 
as slow-release morphine or diacetylmorphine (heroin), are 
only prescribed occasionally in Europe, and are estimated 
to be received by around 3 % of those receiving 
substitution treatment. 
An estimated 700 000 opioid users received substitution 
treatment in the European Union in 2013, and a slight 
downtrend has been observed in these data since 2011 
(Figure 3.6). Between 2010 and 2013, the largest relative 
decreases were observed the Czech Republic (41 %, 
based on estimates), Cyprus (39 %) and Romania (36 %). 
The highest relative increases over the same period were 
observed in Poland (80 %), from a low base, and Greece 
(59 %). When data from Turkey and Norway are included, 
the 2013 estimate for those receiving substitution 
treatment increases to 737 000.
I  Over half of opioid users are in substitution treatment
Coverage of opioid substitution treatment — the 
proportion of those in need receiving the intervention — is 
estimated at more than 50 % of Europe’s problem opioid 
users. This estimate needs to be treated with caution for 
methodological reasons, but in many countries a majority 
of opioid users are, or have been, in contact with treatment 
services. At national level, however, large differences still 
exist in coverage rates, with the lowest estimates reported 
by Latvia, Poland and Lithuania (around 10 % or less) 
(Figure 3.7).
Although less common, alternative treatment options for 
opioid users are available in all European countries. In the 
10 countries providing sufficient data, the coverage of 
treatment approaches not involving substitution 
medication is generally within the range of 4 % to 71 % 
of all problem opioid users in treatment.
FIGURE 3.6
Trends in number of clients in opioid substitution treatment
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I  Responding to diverse needs though targeted interventions
Targeted interventions can facilitate access to treatment 
and ensure that the needs of different groups are met. The 
available information suggests that this kind of approach is 
currently most commonly available to young drug users, 
those referred from the criminal justice system and 
pregnant women (Figure 3.8). Targeted programmes for 
homeless drug users, older drug users and lesbian, gay, 
bisexual and transgender drug users were less frequently 
available, despite many countries reporting that there was 
a need for this kind of provision.
FIGURE 3.8
Availability of drug treatment programmes for target groups in 
Europe (expert ratings, 2013)
FIGURE 3.7
Percentage of problem opioid users receiving substitution treatment (estimate)
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I  Cannabis-specific treatment available in half of countries
The provision of cannabis-specific treatment is increasing 
in Europe, with half of the countries now reporting its 
availability. Elsewhere, cannabis treatment is provided 
within general substance use programmes (Figure 3.9). 
Services for cannabis users can be diverse, ranging from 
brief interventions delivered online, to long-term 
therapeutic engagement in specialist centres. Although 
most treatment for this group takes place in community or 
outpatient settings this is not always the case, with around 
one in five of those entering specialist inpatient drug 
treatment services now being reported to have a primary 
cannabis-related problem.
Treatment for cannabis problems utilises psychosocial 
approaches; family based interventions are often used for 
adolescents and cognitive-behavioural interventions for 
adults. The available evidence supports the use of a 
combination of cognitive-behavioural therapy, motivational 
interviewing and contingency management approaches. In 
addition, there is some evidence to support the use of 
multidimensional family therapy for young cannabis users. 
Internet-based interventions have extended the reach and 
geographical coverage of cannabis programmes. These 
interventions offer a new way to engage with people 
experiencing drug problems and have the potential to 
access some user groups that are not currently in contact 
with specialist drug services.
I Tailoring treatment for ageing drug users
Demographic trends among Europe’s problem drug-using 
population raise important questions about the 
appropriateness of drug treatment interventions for ageing 
clients. Those above the age of 40 will soon comprise the 
majority of problem opioid users in treatment. In addition 
to drug-related health problems, opioid users are also 
increasingly facing health problems related to ageing, 
often exacerbated by lifestyle factors. Clinical guidelines 
that take account of the demographic shift in Europe’s 
problem opioid users are needed. This will support 
effective clinical practice, as issues around drug 
interactions, modes of administration, take-home dosages 
and pain treatment become more complex and important. 
Few countries report the availability of targeted 
programmes for older drug users. This client group is 
generally integrated within existing drug treatment 
services (see Figure 3.10). However, both Germany and 
the Netherlands have set up retirement homes catering for 
the needs of older drug users. In the future, drug treatment 
and care programmes will have to be modified and 
developed if this ageing cohort is to receive an appropriate 
level of care. This is likely to require staff training and 
changes in care provision. As this is a client group with 
relatively poor engagement with the general health system 
and poor adherence to treatment for drug-related 
infections, the importance of a multi-disciplinary approach 
that continues after drug treatment is clear.
FIGURE 3.9
Existence of specialised treatment programmes for cannabis users 
in European countries
 Few countries report the  
 availability of targeted  
 programmes for older  
 drug users 
Cannabis-specic treatment is available
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I Preventing the spread of infectious diseases
Drug users, and particularly those who inject drugs, are at 
risk of contracting infectious diseases through the sharing 
of drug use material and through unprotected sex. 
Preventing the transmission of HIV, viral hepatitis and 
other infections is therefore an important objective for 
European drug policies. For injecting opioid users, 
substitution treatment reduces reported risk behaviour, 
with some studies suggesting that the protective effect 
increases when combined with needle and syringe 
programmes.
Between 2007 and 2013, the reported number of syringes 
distributed through specialised programmes increased 
from 43 million to 49 million in 24 countries representing 
48 % of the EU population. A divergent picture is evident at 
country level, with around half reporting an increase in 
syringe distribution and half a decrease. Among the 12 
countries with recent estimates of injection prevalence, the 
reported number of syringes distributed through 
specialised programmes in 2013 ranged from less than 
one in Cyprus to more than 300 per injecting drug users in 
Estonia and Norway (Figure 3.11).
FIGURE 3.10
Availability of targeted programmes for older drug users  
(expert ratings, 2013)
FIGURE 3.11
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While overall in Europe, the coverage of HIV prevention 
measures has been increasing, significant populations of 
injecting drug users continue to have limited access to 
services. An overview of some top-level indicators of 
potential risk is provided in Figure 3.12. Based on this 
simple analysis, around one-third of the countries display 
some elevated risk, suggesting a need for continued 
vigilance and for increasing the scaling up of HIV 
prevention measures.
I Hepatitis C treatment improves
Prevention measures targeting the transmission of 
hepatitis C virus are similar to those for HIV. At the policy 
level, an increasing number of countries have adopted or 
are preparing specific hepatitis C strategies. Initiatives 
directed at testing and counselling injecting drug users 
have been increasing in the past years, but still remain 
limited. New diagnostic tools (such as the Fibroscan) have 
been introduced, and new medications have reduced 
treatment duration and negative side-effects, facilitating 
compliance. However, despite growing evidence of the 
effectiveness of hepatitis C antiviral treatment for infected 
injecting drug users, reported levels of availability remain 
limited in a number of countries (see Figure 3.13). This 
may in part be due to the high costs of the new 
medications.
FIGURE 3.12
Summary indicators for potential elevated risk for HIV infections among injecting drug users
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trends
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drug use prevalence
and trends 
(transmission risk)
Low substitution 
treatment coverage 
(<30 %)
Low needle and syringe 
coverage 
(<100 syringes per
injecting drug user)
Risk factor present: signicant increase in HIV case reports or HIV prevalence; increase in transmission risk; low intervention coverage.
Risk factors possibly present: HIV or HCV prevalence or transmission risk showing increase at subnational level or consistent but non-signicant increase 
at national level.
None of the following risk factors identied: increase in HIV case reports or prevalence of HIV or HCV; increase in transmission risk; low intervention coverage.
Information not available to ECDC or the EMCDDA.
NB: For information, see the online supplementary table.
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I Preventing overdoses and drug-related deaths
Reducing fatal drug overdoses and other drug-related 
deaths remains a major challenge for public health policy 
in Europe. Targeted responses in this area focus either on 
preventing the occurrence of overdoses, or on improving 
the likelihood of surviving an overdose. Drug treatment, 
particularly opioid substitution treatment, prevents 
overdoses and reduces the mortality risk of drug users. 
Among a selection of interventions targeting drug-related 
deaths, the provision of information and materials on 
overdose prevention is reported to be most widely 
available (Figure 3.14). Training in responding to 
overdoses, including the distribution of the opioid 
antagonist drug naloxone, can save lives in overdose 
situations. However, this form of response is less 
commonly available. New WHO guidelines strongly 
recommend that people who are likely to witness an 
overdose should have access to naloxone and be 
instructed in its administration to enable them to use it for 
the emergency management of suspected opioid 
overdose. Naloxone schemes currently exist in seven 
countries, with schemes established in recent years in 
Denmark, Estonia and Norway, countries where overdose 
rates are high. A recent study from Scotland (UK) showed 
that increased provision of naloxone kits to ‘at risk’ 
prisoners on liberation coincided with a significant 
reduction in opioid-related deaths occurring in the first four 
weeks after prison release. 
One of the aims of supervised drug consumption facilities 
is to reduce the occurrence of overdose and to increase 
the chance of survival should one occur. Six countries 
currently provide such facilities — around 70 in total. In 
recent years, a number of facilities have been closed due 
to falling demand.
I Prison health: a comprehensive response required
Prisoners report higher lifetime rates of drug use than the 
general population and more harmful patterns of use, 
illustrated by recent studies showing that between 6 % and 
31 % of prisoners have ever injected drugs. On admission 
to prison, most users reduce or cease consumption of 
drugs. Illicit drugs do, however, find their way into many 
prisons, and some prisoners continue or even initiate use 
FIGURE 3.13 FIGURE 3.14
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during incarceration. High rates of hepatitis C and other 
infectious diseases have also been observed among 
prisoner populations. The high incidence of drug problems 
among prisoners means that health assessment upon 
prison entry is an important intervention. The WHO have 
recently recommended that a package of prevention 
responses, including free and voluntary testing for 
infectious diseases, distribution of condoms and sterile 
injecting equipment, infectious diseases treatment and 
treatment of drug dependence is made available. 
Many countries have established interagency partnerships 
between prison health services and providers in the 
community. Such partnerships deliver health education 
and treatment interventions in prison and ensure 
continuity of care upon prison entry and release. Generally, 
prison health services remain the responsibility of 
ministries of justice or interior. In some countries, however, 
the ministry of health now has responsibility for the 
delivery of prison health service, potentially facilitating 
greater integration with general health service provision in 
the community.
The availability of opioid substitution treatment in prisons 
is reported by 26 of the 30 countries monitored by the 
EMCDDA, although no activities were reported in three of 
these countries in 2013. Overall, it appears that the level of 
coverage of prisoner populations is increasing, reflecting 
the widespread availability of this intervention in the 
community. Restrictions on eligibility may exist however, 
for example in the Czech Republic and Latvia, treatment in 
prison is limited to those already having a prescription 
prior to incarceration. The provision of clean injecting 
equipment is less common, with only four countries 
reporting its availability in prisons. 
 The high incidence of drug  
 problems among prisoners  
 means that health assessment  
 upon prison entry is an  
 important intervention 
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Annex: national data tables
OPIOIDS
Problem 
opioid 
use 
estimate
Treatment demand indicator, primary drug
Clients in 
substi-
tution 
treatment
Opioid clients as %  
of treatment entrants
% opioid clients injecting  
(main route of administration)
All entrants First-time entrants
Previously 
treated 
entrants
All entrants First-time entrants
Previously 
treated 
entrants
Country cases per 1 000 % (count) % (count) % (count) % (count) % (count) % (count) count
Belgium – 30.8 (2 816) 13 (416) 39 (2 024) 20.1 (547) 14.1 (57) 21.5 (420) 17 482
Bulgaria – 88.8 (1 744) 79.3 (211) 95.2 (954) 73.8 (876) 68.8 (141) 74.4 (585) 3 563
Czech 
Republic
1.5–1.5 17.2 (1 681) 7.8 (362) 25.6 (1 319) 89.4 (1 493) 86.9 (312) 90.1 (1 181) 3 500
Denmark – 17.5 (663) 7.1 (102) 26.3 (502) 23 (20) 33.9 (193) – 7 600
Germany 2.8–3.4 37.1 (29 891) 13.7 (3 217) – – – – 77 300
Estonia – 92.9 (403) 81 (102) 98.6 (284) 84.8 (339) 90.2 (92) 83 (235) 1 166
Ireland – 51.3 (4 451) 29.7 (1 032) 66.8 (3 291) 41.3 (1 762) 33.7 (344) 43.6 (1 362) 9 640
Greece 2.0–2.6 69.3 (3 367) 54.9 (1 145) 80 (2 194) 36.8 (1 227) 32.8 (372) 39.1 (850) 9 973
Spain 1.7–2.6 26.8 (13 333) 11.4 (2 866) 43.7 (10 050) 17.8 (2 195) 11 (295) 19.6 (1 859) 69 111
France – 43.1 (15 641) 27.1 (2 690) 53.5 (11 275) 14.2 (1 836) 6.8 (172) – 163 000
Croatia 3.2–4.0 80.4 (6 315) 24 (270) 90 (5 992) 73.7 (4 581) 42.6 (104) 75.1 (4 446) 6 357
Italy 3.8–4.9 54.7 (18 072) 37.2 (4 782) 65.7 (13 290) 57 (9 678) 44.4 (1 906) 61.3 (7 772) 94 376
Cyprus 1.2–2.1 26.5 (270) 7.7 (37) 43.8 (232) 48.1 (126) 40 (14) 49.3 (112) 180
Latvia 4.1–9.7 52.1 (783) 19.7 (104) 69.6 (679) 63.7 (495) 84.6 (88) 60.5 (407) 328
Lithuania 2.3–2.4 86.8 (1 918) 62.8 (214) 91.9 (1 671) – 100 (140) – 592
Luxembourg 5.0–7.6 50.2 (145) 42.1 (8) 49.8 (116) 48.2 (68) 28.6 (2) 47 (54) 1 254
Hungary 0.4–0.5 5.9 (236) 2.1 (54) 13.6 (160) 70.1 (157) 60.4 (32) 71.8 (112) 786
Malta 6.5–7.7 74.8 (1 352) 33.7 (67) 79.9 (1 285) 61.8 (816) 54.2 (32) 62.2 (784) 1 078
Netherlands 1.1–1.5 10.2 (1 195) 5.1 (343) 17 (852) 4.6 (51) 5.4 (16) 4.3 (35) 8 185
Austria 4.9–5.1 52 (1 537) 29.5 (361) 67.9 (1 176) 43.4 (536) 31.1 (100) 47.8 (436) 24 027
Poland 0.4–0.7 26.4 (724) 8.2 (91) 39.3 (621) 58 (391) 43.4 (36) 60.3 (349) 1 725
Portugal – 54.3 (1 634) 27.3 (380) 77.6 (1 254) 15.9 (238) 11.2 (38) 17.3 (200) 16 858
Romania – 48.8 (802) 33.6 (240) 63.3 (543) 84.5 (622) 84.8 (189) 84.8 (420) 387
Slovenia 4.3–5.8 81.5 (234) 60.6 (57) 91.7 (176) 48.7 (113) 36.8 (21) 52.3 (91) 4 065
Slovakia 1.0–2.5 24.7 (558) 16 (185) 34.1 (363) 66.8 (367) 48.4 (89) 76.4 (272) 408
Finland 3.8–4.5 64.2 (706) 40.4 (65) 69.2 (619) 81.6 (567) 73 (46) 82.5 (504) 2 439
Sweden – 27.3 (7 760) 17.2 (2 211) 35.7 (5 549) 59.6 (140) 33.3 (11) 63.9 (129) 3 425
United 
Kingdom
7.9–8.4 50.3 (49 871) 19.7 (6 813) 66.6 (42 636) 34.5 (16 871) 22.5 (1 484) 36.3 (15 191) 172 513
Turkey 0.2–0.5 76.3 (5 542) 68 (2 540) 85.1 (3 002) 39.7 (2 201) 29.3 (745) 48.5 (1 456) 28 656
Norway 1.9–3.1 26.9 (2 266) – – – – – 7 055
European 
Union
– 41 (168 102) 18.7 (28 425) 57.1 (109 107) 38.2 (46 285) 28.4 (6 153) 43.3 (37 806) 701 449
EU, Turkey 
and Norway
– 41.3 (175 910) 19.9 (30 965) 57.6 (112 109) 30.4 (48 486) 28.5 (6 898) 43.5 (39 262) 737 160
Year and method of estimate for problem opioid use vary between countries.
The treatment demand indicator monitors entrants into treatment within a given year.
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COCAINE
Prevalence estimates Treatment demand indicator, primary drug
General population School population Cocaine clients as % of treatment entrants
% cocaine clients injecting 
(main route of administration)
Lifetime, 
adult 
(15–64)
Last 12 
months, 
young 
adult 
(15–34)
Lifetime, 
students 
(15–16)
All entrants First-time entrants
Previously 
treated 
entrants
All 
entrants
First-
time 
entrants
Previously 
treated 
entrants
Country % % % % (count) % (count) % (count) % (count) % (count) % (count)
Belgium – 2.0 2 15.6 (1 430) 15.2 (488) 15.9 (825) 6 (83) 1.3 (6) 7.1 (57)
Bulgaria 0.9 0.3 4 0 (0) 2.6 (7) 0.3 (3) 0 (0) 0 (0) 0 (0)
Czech 
Republic
0.4 0.3 1 0.2 (19) 0.3 (12) 0.1 (7) 11.1 (2) 16.7 (2) 0 (0)
Denmark 5.2 2.4 2 5.1 (193) 5.8 (84) 5.2 (99) 10.1 (17) 0 (0) –
Germany 3.4 1.6 3 5.9 (4 788) 5.6 (1 322) – – – –
Estonia – 1.3 2 0 (0) 0 (0) 0 (0) – – –
Ireland 6.8 2.8 3 7.8 (680) 9.2 (320) 6.6 (324) 1.7 (11) 0.3 (1) 2.9 (9)
Greece 0.7 0.2 1 5.1 (250) 5.9 (122) 4.6 (127) 19.8 (49) 12.4 (15) 27 (34)
Spain 10.3 3.3 3 39.2 (19 497) 40.2 (10 142) 38.5 (8 855) 2 (365) 1 (95) 3 (260)
France 5.4 2.3 4 6.4 (2 311) 4.1 (411) 7.5 (1 573) 9.9 (192) 4.1 (16) –
Croatia 2.3 0.9 2 1.5 (119) 2.6 (29) 1.3 (84) 0.9 (1) 0 (0) 1.2 (1)
Italy 4.2 1.3 1 25.8 (8 529) 31.4 (4 037) 22.2 (4 492) 3.5 (289) 2.9 (114) 4 (175)
Cyprus 1.3 0.6 4 12.2 (124) 9.3 (45) 14.7 (78) 5.8 (7) 0 (0) 9.3 (7)
Latvia 1.5 0.3 4 0.3 (5) 0.8 (4) 0.1 (1) 0 (0) 0 (0) 0 (0)
Lithuania 0.9 0.3 2 0.6 (14) 1.8 (6) 0.3 (5) – – –
Luxembourg – – – 17.3 (50) 10.5 (2) 18 (42) 39.1 (18) – 39 (16)
Hungary 0.9 0.4 2 2 (81) 2.4 (60) 1.4 (17) 8.9 (7) 8.3 (5) 5.9 (1)
Malta 0.5 – 4 14.4 (260) 32.2 (64) 12.2 (196) 25.6 (65) 11.3 (7) 30.2 (58)
Netherlands 5.2 2.4 2 26.5 (3 113) 22.2 (1 494) 32.3 (1 619) 0.3 (8) 0.3 (4) 0.3 (4)
Austria 2.2 1.2 – 10.2 (301) 11.8 (145) 9 (156) 7.6 (18) 2.7 (3) 12.2 (15)
Poland 0.9 0.3 3 2.4 (67) 1.9 (21) 2.8 (44) 6.3 (4) 4.8 (1) 7.3 (3)
Portugal 1.2 0.4 4 12.9 (388) 17.2 (239) 9.2 (149) 4.1 (14) 1.9 (4) 7.7 (10)
Romania 0.3 0.2 2 0.7 (11) 1.3 (9) 0.2 (2) – – –
Slovenia 2.1 1.2 3 3.5 (10) 6.4 (6) 2.1 (4) 30 (3) 16.7 (1) 50 (2)
Slovakia 0.6 0.4 1 0.6 (13) 0.4 (5) 0.8 (8) 8.3 (1) 0 (0) 14.3 (1)
Finland 1.7 0.6 1 0.1 (1) 0 (0) 0 (0) 100 (1) – –
Sweden – 1.2 1 0.8 (236) 1.2 (151) 0.5 (85) 6.3 (2) 0 (0) 18.2 (2)
United 
Kingdom
9.5 4.2 2 12.9 (12 756) 17.1 (5 888) 10.7 (6 851) 1.7 (204) 0.5 (29) 2.6 (175)
Turkey – – – 1.1 (81) 1.1 (41) 1.1 (40) 0 (0) 0 (0) 0 (0)
Norway 4.2 2.2 1 0.9 (79) – – – – –
European 
Union
4.6 1.9 – 13.5 (55 246) 16.5 (25 113) 13.4 (25 646) 2.8 (1 361) 1.3 (303) 3.6 (830)
EU, Turkey 
and Norway
– – – 13 (55 406) 16.2 (25 154) 13.2 (25 686) 2.8 (1 361) 1.3 (303) 3.6 (830)
Prevalence estimates for the general population are derived from representative national surveys.  The year and method of survey varies by country.
Prevalence estimates for the school population are taken from national school surveys or the ESPAD project.
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AMPHETAMINES
Prevalence estimates Treatment demand indicator, primary drug
General population School population
Amphetamines clients as % of  
treatment entrants
% amphetamines clients injecting 
(main route of administration)
Lifetime, 
adult 
(15–64)
Last 12 
months, 
young 
adult 
(15–34)
Lifetime, 
students 
(15–16)
All entrants First-time entrants
Previously 
treated 
entrants
All entrants First-time entrants
Previously 
treated 
entrants
Country % % % % (count) % (count) % (count) % (count) % (count) % (count)
Belgium – – 2 10.1 (925) 9.1 (292) 11 (574) 13.3 (118) 5.3 (15) 17.7 (97)
Bulgaria 1.2 1.3 5 4.7 (93) 10.9 (29) 1.8 (18) 0 (0) 0 (0) 0 (0)
Czech 
Republic
1.1 0.7 2 70.3 (6 865) 74.2 (3 431) 66.7 (3 434) 78.6 (5 365) 72.6 (2 473) 84.5 (2 892)
Denmark 6.6 1.4 2 9.5 (358) 10.3 (149) 8.9 (170) 3.1 (9) 0 (0) –
Germany 3.1 1.8 4 14.9 (12 026) 18.7 (4 365) – – – –
Estonia – 2.5 3 3 (13) 5.6 (7) 1.4 (4) 76.9 (10) 57.1 (4) 100 (4)
Ireland 4.5 0.8 2 0.6 (52) 0.9 (32) 0.4 (18) 5.9 (3) 9.7 (3) 0 (0)
Greece 0.1 0.1 2 0.2 (12) 0.3 (7) 0.2 (5) 0 (0) 0 (0) 0 (0)
Spain 3.8 1.2 2 1 (512) 1.2 (307) 0.8 (186) 0.6 (3) 0.7 (2) 0.6 (1)
France 2.2 0.7 4 0.3 (98) 0.2 (22) 0.3 (60) 22.5 (18) 15.8 (3) –
Croatia 2.6 1.6 1 0.9 (69) 2 (22) 0.7 (46) 0 (0) 0 (0) 0 (0)
Italy 1.8 0.1 1 0.2 (51) 0.3 (37) 0.1 (14) 2 (1) 2.9 (1) 0 (0)
Cyprus 0.7 0.4 4 2.6 (26) 1.7 (8) 3.4 (18) 7.7 (2) 0 (0) 11.1 (2)
Latvia 2.2 0.6 4 15.1 (227) 21 (111) 11.9 (116) 68.2 (152) 64.2 (70) 71.9 (82)
Lithuania 1.2 0.5 3 3.4 (76) 10 (34) 1.9 (34) – – –
Luxembourg – – – 0 (0) 0 (0) 0 (0) – – –
Hungary 1.8 1.2 6 11.6 (461) 11.6 (297) 11 (130) 15.3 (68) 11.3 (33) 24.2 (30)
Malta 0.3 – 3 0.2 (4) 0 (0) 0.2 (4) 25 (1) - 25 (1)
Netherlands 3.1 – 1 6.5 (760) 6.6 (445) 6.3 (315) 0.6 (4) 0.5 (2) 0.7 (2)
Austria 2.5 0.9 – 3.4 (102) 4.7 (58) 2.5 (44) 1.2 (1) 2 (1) 0 (0)
Poland 2.9 1.4 4 25.9 (711) 25.8 (287) 26.5 (419) 10.8 (76) 3.9 (11) 15.7 (65)
Portugal 0.5 0.1 3 0.1 (2) 0.1 (1) 0.1 (1) 0 (0) 0 (0) –
Romania 0.1 0.0 2 0.5 (8) 1 (7) 0 (0) – – –
Slovenia 0.9 0.8 2 0.7 (2) 1.1 (1) 0.5 (1) – – –
Slovakia 0.5 0.3 1 43.2 (978) 46.4 (535) 39.9 (425) 31.8 (300) 27.1 (142) 38 (154)
Finland 2.3 1.6 – 11 (121) 11.8 (19) 10.8 (97) 76.7 (89) 52.6 (10) 81.9 (77)
Sweden – 1.3 0 0.4 (112) 0 (6) 0.7 (105) 78.3 (83) 80 (4) 78 (78)
United 
Kingdom
11.1 1.5 1 2.7 (2 725) 3.1 (1 058) 2.6 (1 656) 24 (607) 13 (125) 31.1 (482)
Turkey 0.1 0.1 2 0 (0) 0 (0) 0 (0) – – –
Norway 3.7 1.1 1 13.1 (1 104) – – – – –
European 
Union
3.5 1.0 – 6.7 (27 389) 7.6 (11 567) 4.1 (7 894) 47 (6 910) 41.9 (2 899) 53.6 (3 967)
EU, Turkey 
and Norway
– – – 6.7 (28 493) 7.4 (11 567) 4.1 (7 894) 47 (6 910) 41.9 (2 899) 53.6 (3 967)
TABLE A3
78
European Drug Report 2015: Trends and Developments
ECSTASY
Prevalence estimates Treatment demand indicator, primary drug
General population School population Ecstasy clients as % of treatment entrants
Lifetime,  
adult (15–64)
Last 12 months, 
young adult 
(15–34)
Lifetime, 
students 
(15–16)
All entrants First-time  entrants
Previously 
treated entrants
Country % % % % (count) % (count) % (count)
Belgium – – 2 0.5 (43) 0.7 (23) 0.4 (19)
Bulgaria 2.0 2.9 4 0.1 (1) 0 (0) 0.1 (1)
Czech Republic 5.1 3.0 3 0.1 (8) 0.1 (4) 0.1 (4)
Denmark 2.3 0.7 1 0.3 (13) 0.5 (7) 0.3 (5)
Germany 2.7 0.9 2 – – –
Estonia – 2.3 3 0 (0) 0 (0) 0 (0)
Ireland 6.9 0.9 2 0.5 (43) 0.8 (27) 0.3 (16)
Greece 0.4 0.4 2 0.2 (8) 0.2 (5) 0.1 (3)
Spain 4.3 1.5 2 0.3 (134) 0.4 (103) 0.1 (29)
France 4.2 2.3 3 0.5 (186) 0.2 (22) 0.6 (122)
Croatia 2.5 0.5 2 0.3 (27) 0.6 (7) 0.3 (19)
Italy 1.8 0.1 1 0.2 (55) 0.2 (23) 0.2 (32)
Cyprus 0.9 0.3 3 0.1 (1) 0 (0) 0.2 (1)
Latvia 2.7 0.8 4 0.2 (3) 0.4 (2) 0.1 (1)
Lithuania 1.3 0.3 2 0 (1) 0 (0) 0.1 (1)
Luxembourg – – – 0.3 (1) 0 (0) 0.4 (1)
Hungary 2.4 1.0 4 1.7 (69) 1.7 (43) 2 (23)
Malta 0.7 – 3 1.2 (22) 3.5 (7) 0.9 (15)
Netherlands 6.2 3.1 4 0.6 (67) 0.8 (55) 0.2 (12)
Austria 2.3 1.0 – 0.8 (23) 1.1 (13) 0.6 (10)
Poland 1.1 0.3 2 0.2 (6) 0.1 (1) 0.3 (5)
Portugal 1.3 0.6 3 0.2 (5) 0.4 (5) 0 (0)
Romania 0.7 0.4 2 0.1 (1) 0.1 (1) 0 (0)
Slovenia 2.1 0.8 2 0 (0) 0 (0) 0 (0)
Slovakia 1.9 0.9 0 0.1 (2) 0.1 (1) 0.1 (1)
Finland 1.8 1.1 2 0.3 (3) 0.6 (1) 0.2 (2)
Sweden – 1.0 1 0 (3) 0 (1) 0 (1)
United Kingdom 9.3 3.0 2 0.3 (325) 0.7 (232) 0.1 (92)
Turkey 0.1 0.1 2 0.8 (55) 1.1 (41) 0.4 (14)
Norway 2.3 1.0 1 0 (0) – –
European Union 3.6 1.4 – 0.3 (1 050) 0.4 (583) 0.2 (415)
EU, Turkey and 
Norway
– – – 0.3 (1 105) 0.4 (624) 0.2 (429)
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CANNABIS
Prevalence estimates Treatment demand indicator, primary drug
General population School population Cannabis clients as % of treatment entrants
Lifetime, adult 
(15–64)
Last 12 months, 
young adult 
(15–34)
Lifetime, 
students 
(15–16)
All entrants First-time  entrants
Previously 
treated entrants
Country % % % % (count) % (count) % (count)
Belgium 14.3 11.2 21 33.6 (3 077) 54.3 (1 744) 23.1 (1 201)
Bulgaria 7.5 8.3 22 3.9 (77) 4.5 (12) 1.8 (18)
Czech Republic 22.8 21.6 42 11 (1 077) 16.5 (763) 6.1 (314)
Denmark 35.6 17.6 18 63.4 (2 397) 72.6 (1 048) 55.5 (1 061)
Germany 23.1 11.1 19 36.3 (29 252) 56.1 (13 138) –
Estonia – 13.6 24 3.7 (16) 12.7 (16) 0 (0)
Ireland 25.3 10.3 18 28.9 (2 511) 47 (1 631) 16 (790)
Greece 8.9 3.2 8 21.5 (1 045) 35.4 (737) 11 (302)
Spain 30.4 17.0 28 29.9 (14 869) 43.6 (10 982) 14.8 (3 402)
France 40.9 22.1 39 44.1 (16 020) 62.5 (6 206) 32.3 (6 804)
Croatia 15.6 10.5 18 13.3 (1 047) 58.4 (658) 5.7 (381)
Italy 21.7 8.0 16 17.4 (5 766) 28 (3 593) 10.7 (2 173)
Cyprus 9.9 4.2 7 56.8 (579) 80.5 (388) 35.3 (187)
Latvia 12.5 7.3 24 27.3 (411) 51.4 (272) 14.3 (139)
Lithuania 10.5 5.1 20 2.9 (65) 11.7 (40) 1.3 (23)
Luxembourg – – – 31.1 (90) 47.4 (9) 30.5 (71)
Hungary 8.5 5.7 19 61 (2 429) 70 (1 787) 43.4 (511)
Malta 4.3 – 10 7.9 (142) 25.1 (50) 5.7 (92)
Netherlands 25.7 13.7 27 47.8 (5 613) 56.7 (3 826) 35.7 (1 787)
Austria 14.2 6.6 14 30 (887) 50.6 (620) 15.4 (267)
Poland 12.2 8.1 23 33.4 (914) 51.6 (575) 20.3 (321)
Portugal 9.4 5.1 16 26.8 (806) 48.4 (674) 8.2 (132)
Romania 1.6 0.6 7 17 (279) 27.3 (195) 7.9 (68)
Slovenia 15.8 10.3 23 12.5 (36) 31.9 (30) 3.1 (6)
Slovakia 10.5 7.3 16 24.6 (557) 32 (369) 16.6 (177)
Finland 18.3 11.2 12 14.6 (161) 34.2 (55) 10.8 (97)
Sweden – 7.1 5 13.2 (3 763) 22.4 (2 881) 5.7 (882)
United Kingdom 29.9 11.2 22 26.8 (26 618) 48.6 (16 775) 15.3 (9 771)
Turkey 0.7 0.4 4 12.7 (920) 17.5 (653) 7.6 (267)
Norway 23.3 12.0 5 20.3 (1 705) – –
European Union 23.3 11.7 – 29.4 (120 504) 45.5 (69 074) 16.2 (30 977)
EU, Turkey and 
Norway
– – – 28.9 (123 129) 44.8 (69 727) 16.1 (31 244)
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OTHER INDICATORS
Drug-induced deaths 
(aged 15–64)
HIV diagnoses attributed 
to injecting drug use
Injecting drug  
use estimate
Syringes distributed 
through specialised 
programmes
Country cases per million population (count)
cases per million 
population (count)
cases per  
1 000 population count
Belgium 10.5 (77) 1.5 (17) 2.5–4.8 907 504
Bulgaria 4.3 (21) 4.5 (33) – 431 568
Czech Republic 5.1 (37) 0.6 (6) 5.9–6.0 6 181 134
Denmark 60 (218) 2.3 (13) – –
Germany 17.6 (956) 1.2 (100) – –
Estonia 126.8 (111) 54.5 (72) 4.3–10.8 2 183 933
Ireland 58.5 (177) 3.9 (18) – 360 041
Greece – 22.4 (248) 0.6–0.9 429 517
Spain 12.2 (383) 3.1 (145) 0.3–0.4 2 684 251
France 6.8 (283) 1 (67) – –
Croatia 16.8 (48) 0 (0) 0.3–0.6 273 972
Italy 8.9 (343) 2.7 (162) – –
Cyprus 4.9 (3) 0 (0) 0.2–0.5 0
Latvia 8.1 (11) 38 (77) 7.3–11.7 341 421
Lithuania 27.1 (54) 20.9 (62) – 168 943
Luxembourg 29.7 (11) 9.3 (5) 4.5–6.9 191 983
Hungary 4.6 (31) 0.1 (1) 0.8 435 817
Malta 10.4 (3) 7.1 (3) – 357 691
Netherlands 10.2 (113) 0.3 (5) 0.2–0.2 –
Austria 24.2 (138) 2.5 (21) – 4 762 999
Poland 7.6 (207) 1 (39) – –
Portugal 3.0 (21) 7.4 (78) – 950 652
Romania 2.2 (30) 7.4 (149) – 2 051 770
Slovenia 19.9 (28) 1 (2) – 513 272
Slovakia 6.5 (25) 0 (0) – 321 339
Finland 54.3 (191) 0.6 (3) 4.1–6.7 3 834 262
Sweden 69.7 (426) 0.8 (8) – 229 362
United Kingdom 44.6 (1 858) 1.8 (112) 2.9–3.2 9 457 256 (1)
Turkey 4.4 (224) 0.1 (4) – –
Norway 69.6 (232) 1.6 (8) 2.2–3.0 3 011 000
European Union 17.3 (5 804) 2.9 (1 446) – –
EU, Turkey and 
Norway
16 (6 260) 2.5 (1 458) – –
Injecting drug use estimates are derived by indirect methods, with year of estimate varying between countries.
(1) Data refer to Scotland and Wales (2013) and Northern Ireland (2012).
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SEIZURES
Heroin Cocaine Amphetamines Ecstasy
Quantity 
seized
Number of 
seizures
Quantity 
seized
Number of 
seizures
Quantity 
seized
Number of 
seizures Quantity seized
Number of 
seizures
Country kg count kg count kg count tablets (kg) count
Belgium 1 182 2 431 6 486 3 653 216 3 085 37 152 (–) 1 338
Bulgaria 157 32 20 – 193 8 4 169 (29) –
Czech Republic 5 38 36 106 70 495 5 061 (0.04) 114
Denmark 14 461 681 2 286 341 2 167 7 706 (–) 590
Germany 270 3 065 1 315 3 622 1 339 12 801 480 839 (–) 2 233
Estonia 0 2 2 47 28 290 3 341 (0.2) 92
Ireland 61 690 66 366 23 114 465 083 (–) 464
Greece 235 2 158 706 437 16 81 34 579 (0.4) 47
Spain 291 6 502 26 701 38 033 497 3 471 154 732 (–) 2 301
France 570 – 5 612 – 501 – 414 800 (–) –
Croatia 10 167 9 171 13 414 0 (0.9) 170
Italy 882 2 560 4 966 6 031 103 128 4 713 (17) 136
Cyprus 0.7 16 3 105 1 38 504 (0.1) 14
Latvia 0.7 288 1 34 46 744 60 (0.003) 18
Lithuania 13 100 3 12 71 97 54 (0.5) 13
Luxembourg 4 127 1 103 5 6 13 (–) 3
Hungary 6 32 8 117 75 586 17 664 (2) 181
Malta 1 51 4 115 0 3 30 375 (–) 45
Netherlands (1) 750 – 10  000 – 681 – – –
Austria 80 346 25 992 29 859 5 768 (–) 119
Poland 49 – 21 – 685 – 45 997 (–) –
Portugal 55 792 2 440 1 108 5 48 2 160 (1) 80
Romania 112 273 53 75 0 42 27 506 (0.04) 142
Slovenia 7 339 3 196 16 273 922 (0.9) 53
Slovakia 0.2 73 1 23 4 634 47 (–) 17
Finland 0.2 113 5 205 91 3 149 121 600 (–) 795
Sweden 6 485 81 1 452 677 4 541 26 919 (16) 743
United Kingdom (1) 831 10 648 3 324 18 569 1 491 6 515 1 173 100 (–) 3 716
Turkey 13 480 6 096 450 863 1 242 132 4 441 217 (–) 4 274
Norway 55 1 192 188 1 086 514 7 229 7 298 (3) 411
European Union 5 593 31 789 62 573 77 858 7 217 40 589 3 064 864 (68) 13 424
EU, Turkey and 
Norway
19 128 39 077 63 211 79 807 8 973 47 950 7 513 379 (71) 18 109
Amphetamines includes amphetamine and methamphetamine.
(1) Seizures data refer to 2012.
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SEIZURES (continued)
Cannabis resin Herbal cannabis Cannabis plants
Quantity seized Number of seizures Quantity seized
Number of 
seizures Quantity seized
Number of 
seizures
Country kg count kg count plants (kg) count
Belgium 4 275 5 529 14 882 23 900 396 758 (–) 1 212
Bulgaria 5 9 579 69 18 126 (24) 11
Czech Republic 1 28 735 875 73 639 (–) 361
Denmark 3 292 11 030 394 1 896 – (5634) 645
Germany 1 770 5 638 4 827 28 875 107 766 (–) 2 026
Estonia 109 24 51 524 – (16) 42
Ireland 677 367 1 102 1 770 6 309 (–) 427
Greece 8 143 20 942 6 743 23 008 (0) 599
Spain 319 257 180 342 16 298 172 341 176 879 (–) 2 305
France 70 918 – 4 758 – 141 374 (–) –
Croatia 5 359 1 047 4 171 3 957 (–) 213
Italy 36 347 5 261 28 821 5 701 894 862 (–) 1 227
Cyprus 1 16 99 849 403 (–) 62
Latvia 106 28 29 412 – (344) 31
Lithuania 1 088 11 124 199 – (–) –
Luxembourg 8 81 11 832 8 (–) 6
Hungary 5 103 863 2 040 5 307 (–) 196
Malta 1 71 10 85 27 (–) 3
Netherlands (1) 2 200 – 12 600 – 1 218 000 (–) –
Austria 130 1 512 1 432 8 270 – (196) 327
Poland 208 – 1 243 – 69 285 (–) –
Portugal 8 681 3 087 96 559 8 462 (–) 354
Romania 25 284 165 1 799 8 835 (110) 79
Slovenia 0.5 73 810 3 673 9 515 (–) 212
Slovakia 0.0 21 81 1 307 1 039 (–) 32
Finland 122 1 467 285 6 167 23 000 (63) 3 409
Sweden 1 160 6 937 928 9 221 – (–) –
United Kingdom (1) 13 432 17 360 13 243 148 746 555 625 (–) 15 846
Turkey 94 279 5 331 180 101 60 742 – (–) 3 706
Norway 2 283 11 875 491 5 444 – (159) 386
European Union 463 831 239 781 126 455 431 024 3 742 184 (6 387) 29 625
EU, Turkey and 
Norway
560 393 256 987 307 047 497 210 3 742 184 (6 546) 33 717
(1) Seizures data refer to 2012, apart from the number of cannabis plants seized in the Netherlands, which refers to 2013.
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HOW TO OBTAIN EU PUBLICATIONS
Free publications
one copy:
via EU Bookshop (http://bookshop.europa.eu)
more than one copy or posters/maps:
from the European Union’s representations  
(http://ec.europa.eu/represent_en.htm); 
from the delegations in non-EU countries  
(http://eeas.europa.eu/delegations/index_en.htm); 
by contacting the Europe Direct service  
(http://europa.eu/europedirect/index_en.htm) or
calling 00 800 6 7 8 9 10 11  
(freephone number from anywhere in the EU) (*).
(*) The information given is free, as are most calls (though 
some operators, phone boxes or hotels may charge you).
Priced publications
via EU Bookshop (http://bookshop.europa.eu)
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About this report
The Trends and Developments report presents a 
top-level overview of the drug phenomenon in Europe, 
covering drug supply, use and public health problems 
as well as drug policy and responses. Together with the 
online Statistical Bulletin, Country Overviews and 
Perspectives on Drugs, it makes up the 2015 European 
Drug Report package.
About the EMCDDA
The European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) is the central source and 
confirmed authority on drug-related issues in Europe. 
For over 20 years, it has been collecting, analysing and 
disseminating scientifically sound information on drugs 
and drug addiction and their consequences, providing 
its audiences with an evidence-based picture of the 
drug phenomenon at European level.
The EMCDDA’s publications are a prime source of 
information for a wide range of audiences including: 
policymakers and their advisors; professionals and 
researchers working in the drugs field; and, more 
broadly, the media and general public. Based in Lisbon, 
the EMCDDA is one of the decentralised agencies of 
the European Union.
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